

CANCER

Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis

Claire Vennin,^{1,2*} Venessa T. Chin,^{1,2*} Sean C. Warren,^{1,2†} Morghan C. Lucas,^{1,2†} David Herrmann,^{1,2} Astrid Magenau,^{1,2} Pauline Melenec,^{1,2} Stacey N. Walters,^{1,2} Gonzalo del Monte-Nieto,^{2,3} James R. W. Conway,^{1,2} Max Nobis,^{1,2} Amr H. Allam,^{1,2} Rachael A. McCloy,^{1,2} Nicola Currey,^{1,2} Mark Pinese,^{1,2} Alice Boulghourjian,¹ Anais Zaratzian,¹ Arne A. S. Adam,³ Celine Heu,⁴ Adnan M. Nagrial,¹ Angela Chou,^{1,2,5} Angela Steinmann,¹ Alison Drury,¹ Danielle Froio,¹ Marc Giry-Laterriere,^{1,2} Nathaniel L. E. Harris,^{1,6} Tri Phan,^{1,2} Rohit Jain,^{7,8} Wolfgang Weninger,^{7,8,9} Ewan J. McGhee,¹⁰ Renee Whan,³ Amber L. Johns,^{1,11,12,13} Jaswinder S. Samra,^{10,13,14} Lorraine Chantrill,^{1,13,14} Anthony J. Gill,^{1,11,12,13,15} Maija Kohonen-Corish,^{1,2,16} Richard P. Harvey,^{2,3,17} Andrew V. Biankin,^{13,18,19} Australian Pancreatic Cancer Genome Initiative (APGI),¹³ T. R. Jeffrey Evans,¹⁰ Kurt I. Anderson,¹⁰ Shane T. Grey,^{1,2} Christopher J. Ormandy,^{1,2} David Gallego-Ortega,^{1,2} Yingxiao Wang,²⁰ Michael S. Samuel,²¹ Owen J. Sansom,¹⁰ Andrew Burgess,^{1,2} Thomas R. Cox,^{1,2} Jennifer P. Morton,¹⁰ Marina Pajic,^{1,2*‡} Paul Timpson^{1,2*‡}

The emerging standard of care for patients with inoperable pancreatic cancer is a combination of cytotoxic drugs gemcitabine and Abraxane, but patient response remains moderate. Pancreatic cancer development and metastasis occur in complex settings, with reciprocal feedback from microenvironmental cues influencing both disease progression and drug response. Little is known about how sequential dual targeting of tumor tissue tension and vasculature before chemotherapy can affect tumor response. We used intravital imaging to assess how transient manipulation of the tumor tissue, or “priming,” using the pharmaceutical Rho kinase inhibitor Fasudil affects response to chemotherapy. Intravital Förster resonance energy transfer imaging of a cyclin-dependent kinase 1 biosensor to monitor the efficacy of cytotoxic drugs revealed that priming improves pancreatic cancer response to gemcitabine/Abraxane at both primary and secondary sites. Transient priming also sensitized cells to shear stress and impaired colonization efficiency and fibrotic niche remodeling within the liver, three important features of cancer spread. Last, we demonstrate a graded response to priming in stratified patient-derived tumors, indicating that fine-tuned tissue manipulation before chemotherapy may offer opportunities in both primary and metastatic targeting of pancreatic cancer.

INTRODUCTION

A number of new therapeutics have been exploited to improve upon gemcitabine (Gem) in pancreatic cancer (PC). Recently, the addition of nab-paclitaxel (Abraxane) to Gem improved patient survival from 6.6 to 8.7 months (1). Although the improvements found with the antimetastatic Abraxane are encouraging and the combination is rapidly becoming a first-line treatment in this aggressive disease (2), there is an urgent need to improve upon this moderate shift in patient survival.

The actin cytoskeleton and its prototypical regulatory proteins Rho guanosine triphosphatases (GTPases) are commonly hijacked by many cancers to drive tumor progression (3–6). In particular, altering cytoskeleton-based cell contractility affects not only coordinated cancer cell protrusion during invasion but also the bidirectional interaction between stromal and cancer cells to induce tissue stiffening and drive tumor survival, proliferation, and progression (7–10). Hence, targeting tissue architecture via Rho GTPase inhibition to alter tissue stiffness, cellular rheology, vasodilation, or mechanoplasticity is an emerging area of potential therapeutic intervention in cancer (3, 5, 11–14).

Optimizing preclinical disease models in drug discovery requires innovative approaches to assess drug response in live tissue at the single-cell and molecular levels. Intravital imaging offers insights into how cells behave in their native environment and provides a dynamic four-

dimensional (4D) molecular readout of therapeutic response, undetectable in vitro (15, 16). Here, we derived primary and invasive cells from both the Pdx1-Cre, LSL-Kras^{G12D/+}, LSL-Trp53^{R172H/+} (KPC) mouse model (17–21) and pancreatic patient-derived xenografts (PDXs) and engineered them to express the highly validated cyclin-dependent kinase 1 (CDK1) Förster resonance energy transfer (FRET) biosensor (22, 23). We monitored CDK1 activity as a surrogate marker of M-phase cell cycle arrest induced by Gem/Abraxane (22–27). Upon investigating the ultrastructure, integrity, and stiffness of the extracellular matrix (ECM) in complex organotypic matrices in response to transient priming with the ROCK inhibitor Fasudil (HA-1077) (28), we mapped PC cell response to Gem/Abraxane in live tumor tissues during disease progression. First, this was achieved through spatiotemporal monitoring of the response to Gem/Abraxane at distinct sites within live primary tumors and PDXs, whereas assessment in liver metastases revealed a multisite improvement in response to chemotherapy after transient dual manipulation of tissue tension and tumor vasculature with Fasudil. Second, priming impaired tumor cell extravasation efficiency, resistance to shear stress, and metastatic niche remodeling within the liver, reducing spread in secondary sites. Last, we reveal a graded response to transient priming regimens relative to ECM found in PDXs from the Australian Pancreatic Cancer Genome Initiative (APGI) cohort (29). Collectively,

2017 © The Authors,
some rights reserved;
exclusive licensee
American Association
for the Advancement
of Science.

Downloaded from <http://stm.sciencemag.org/> on April 5, 2017

we present preclinical evidence that tailored, fine-tuned tissue priming before chemotherapy may offer opportunities in both primary and metastatic targeting in PC.

RESULTS

Priming the stroma via ROCK inhibition disrupts ECM integrity

The effect of ROCK inhibition on ECM integrity was assessed using fibroblast-driven contraction assays, which revealed a decrease in contraction upon treatment with Fasudil (Fig. 1A). Immunohistochemical (IHC) analysis of ROCK signaling in matrices confirmed that Fasudil inhibits the downstream targets of ROCK, pMLC2, and pMYPT1 (fig. S1, A and B) (30), whereas 2D and 3D cell proliferation analyses indicated that impairment of matrix contraction was independent of changes in fibroblast proliferation and survival (fig. S1, C to E).

Second harmonic generation (SHG) imaging (31) and polarized light microscopy of picosirius red staining (32, 33) of contracted collagen matrices revealed a reduction in fibrillar collagen coverage upon ROCK inhibition compared to control (Fig. 1, B to D, and fig. S1F), whereas collagen production was unaltered (Fig. 1, E and F). Live monitoring of fibroblast-ECM interactions (Fig. 1G and movie S1) (34) demonstrated uncoordinated, shorter, and unstable fibroblast protrusions in Fasudil-treated conditions, as well as increased cell circularity (Fig. 1H). Analysis of matrix ultrastructure using gray-level co-occurrence matrix (GLCM) (35) and scanning electron microscopy confirmed a disorganized ECM network in Fasudil-treated condition (Fig. 1, I to K), and atomic force microscopy measurements revealed a reduction in matrix stiffness for primed matrices (Fig. 1L). Similar results were observed for matrices treated with the structurally unrelated ROCK inhibitor Y-27632 (fig. S1, G to L), confirming that ROCK targeting disrupts matrix integrity.

¹The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales 2010, Australia. ²St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, New South Wales 2010, Australia. ³Developmental and Stem Cell Biology Division, Victor Chang Cardiac Research Institute, Sydney, New South Wales 2010, Australia. ⁴Biomedical Imaging Facility, Mark Wainwright Analytical Centre, Lowy Cancer Research Centre, University of New South Wales, Sydney, New South Wales 2052, Australia. ⁵Department of Pathology, St. Vincent's Hospital, Sydney, New South Wales 2010, Australia. ⁶Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, New South Wales 2522, Australia. ⁷Immune Imaging Program, Centenary Institute, University of Sydney, Sydney, New South Wales 2006, Australia. ⁸University of Sydney Medical School, Sydney, New South Wales 2006, Australia. ⁹Department of Dermatology, Royal Prince Alfred Hospital, Camperdown, New South Wales 2050, Australia. ¹⁰Cancer Research UK Beatson Institute, Glasgow, Scotland G61 1BD, U.K. ¹¹Cancer Diagnosis and Pathology Research Group, Kolling Institute of Medical Research and Royal North Shore Hospital, Sydney, New South Wales 2065, Australia. ¹²University of Sydney, Sydney, New South Wales 2006, Australia. ¹³Australian Pancreatic Cancer Genome Initiative ¹⁴Department of Surgery, Royal North Shore Hospital, Sydney, New South Wales 2065, Australia. ¹⁵Macarthur Cancer Therapy Centre, Campbelltown Hospital, Sydney, New South Wales 2560, Australia. ¹⁶School of Medicine, Western Sydney University, Penrith, Sydney, New South Wales 2751, Australia. ¹⁷School of Biotechnology and Biomolecular Science, University of New South Wales, Sydney, New South Wales 2052, Australia. ¹⁸Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Scotland G61 1BD, U.K. ¹⁹West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Scotland G61 1BD, U.K. ²⁰Department of Bioengineering, Institute of Engineering in Medicine, University of California, San Diego, San Diego, CA 92121, USA. ²¹Centre for Cancer Biology, SA Pathology and University of South Australia School of Medicine, University of Adelaide, Adelaide, South Australia 5000, Australia.

*These authors contributed equally to this work.

†These authors contributed equally to this work.

‡Corresponding author. Email: m.pajic@garvan.org.au (M. Pajic); p.timpson@garvan.org.au (P.T.)

Recent studies assessing the effect of stromal manipulation via long-term interference with ECM remodeling have yielded conflicting data on the utility of stromal targeting in limiting the progression of PC (10, 12, 36–43). We therefore sought to assess whether fine-tuned transient interference with stromal tension affects PC progression and drug response (10).

The scheduling of priming regimens influences PC cell invasion and Gem/Abraxane efficacy

We examined cancer cell invasion in a 3D organotypic model using primary PC cells established from KPC mice (17, 18, 44, 45). 3D organotypic matrices were treated with Fasudil either during contraction (priming) or during invasion (later treatment) (Fig. 2A). KPC cell invasion was decreased in matrices primed with Fasudil compared to control (Fig. 2, B and C). Later Fasudil treatment alone did not significantly affect KPC invasion, and continuous treatment during both contraction and invasion had no advantage over priming of the matrix alone (Fig. 2, B and C), demonstrating that transient ROCK targeting can impair PC invasion and could minimize the need for long-term treatments.

Because mechanical cues provided by the ECM have been suggested to limit response to chemotherapy (46, 47), we next investigated whether transient Fasudil priming would increase KPC cell response to subsequent Gem/Abraxane treatment in organotypic matrices. Ki67 and cleaved caspase-3 staining demonstrated that Gem/Abraxane treatment alone reduced cell proliferation and induced cell apoptosis (Fig. 2, D and E, black bars versus green bars), as expected given their clinical use (2). This was improved in Fasudil-primed settings (Fig. 2, D and E, green bars versus blue bars), although Fasudil priming alone had no effect on KPC cell proliferation and apoptosis in this context (Fig. 2, D and E, black bars versus orange bars).

Although these static markers of tumor behavior provide an initial insight into tumor response, they lack the capacity to monitor more detailed temporal and spatial information. We therefore opted to longitudinally map Gem/Abraxane therapy using a CDK1-FRET biosensor (22, 23) as a molecular readout of cell cycle arrest induced by chemotherapy (27).

A CDK1 biosensor monitors PC cell response to Gem/Abraxane

Primary KPC cells were engineered to express a CDK1-FRET biosensor, and the activity of CDK1 was measured by fluorescence lifetime imaging microscopy of the FRET signal (FLIM-FRET; Fig. 3A). In the lifetime color maps, low CDK1 activity is represented by longer lifetimes and yellow/red colors, whereas high CDK1 activity is represented by shorter lifetimes and blue/green colors, and areas with no signal are black (Fig. 3B and fig. S2A).

To confirm that the CDK1-FRET biosensor reports changes in CDK1 activity, KPC cells were treated with Abraxane to arrest them in mitosis, where CDK1 activity is high (22–27), followed by treatment with the specific CDK1 inhibitor RO3306 (fig. S2, B and C) (48). Abraxane induced a decrease in the fluorescence lifetimes, indicating active CDK1, and treatment with RO3306 reverted the lifetimes to values similar to control, confirming CDK1 inhibition (fig. S2, C and D, and movie S2). Using the lifetime distribution, we stratified cells as “CDK1 ON” or “CDK1 OFF” and confirmed changes in CDK1 activity by Western blot analysis of pY15-CDK1 (fig. S2, E and F). Similarly, FLIM-FRET analysis of cells in different stages of the cell cycle confirmed accumulation of active CDK1 in mitotic cells compared to cells in interphase (fig. S2, G to I, and movie S3). We also confirmed that expression of the CDK1

Fig. 1. ROCK inhibition disrupts collagen matrix integrity.

(A) Schematic of contraction assay (left), representative images of telomerase-immortalized fibroblast (TIF)-collagen matrices, and quantification of matrix area \pm Fasudil over time. $n = 3$ biological repeats with three matrices per condition and per repeat. All individual data points are represented with SD, and statistical analysis was performed using the average values of the three biological repeats.

(B) Representative maximum intensity projections of SHG signal and quantification of SHG signal and quantification of SHG signal at peak in TIF-collagen matrices after 12 days of contraction \pm Fasudil. $n = 3$ biological repeats with three matrices per condition and per repeat.


(C) Bright-field and polarized light imaging of picosirius red-stained organotypic matrices primed \pm Fasudil and quantification of the intensity of the signal acquired via polarized light. $n = 3$ biological repeats with three matrices per condition and per repeat.

(D) Contribution and quantification of signal emitted from fibers with high, medium, and low birefringence normalized to total signal acquired via polarized imaging of picosirius red-stained collagen matrices \pm Fasudil. Thick remodeled collagen fibers are highly birefringent (red-orange), whereas less remodeled fibers have a lower birefringence (green). $n = 3$ biological repeats with three or two matrices per condition and per repeat.

(E) Herovici's staining and quantification of collagen content in collagen matrices \pm Fasudil. $n = 3$ biological repeats with three matrices per condition and per repeat. n.s., not significant.

(F) Real-time quantitative polymerase chain reaction analysis of *Col1a1* mRNA in TIFs \pm Fasudil exposure for 72 hours. $n = 3$ biological repeats.

(G) Time-lapse tracking of fibroblast-ECM interactions on day 6 of contraction \pm Fasudil and color-coded overlay of single protrusion tracking (red, $t = 0$ min; light green, $t = 100$ min; yellow, $t = 200$ min; blue, $t = 300$ min; dark green, $t = 400$ min; purple, $t = 500$ min). Scale bars, 100 μ m. **(H)** Number of cell protrusions over time in control (left) and Fasudil-primed (right) matrices. Traces are color-coded according to the initial protrusion number (color key informs on initial number of protrusions at $t = 0$ min). The graphs on the right indicate protrusion number, length, persistence, and cell circularity in collagen matrices \pm priming with Fasudil (30 cells per group and $n = 3$ independent matrices).






Fig. 2. Scheduling of priming regimens influences PC cell invasion and Gem/Abraxane efficacy. (A) Schematic representation of organotypic invasion assay with KPC cells. Matrices were primed with Fasudil during contraction and/or treated with Fasudil during KPC cell invasion. (B) Representative images of pancytokeratin staining in organotypic matrices. (C) Quantification of KPC cell invasive index upon priming, later, and priming + later treatment with Fasudil. (D) Representative images of Ki67 staining as a marker of cell proliferation and quantification of KPC cells positive for Ki67 (ratio normalized to control) in organotypic matrices after 72 hours of treatment with Gem/Abraxane. (E) Representative images of cleaved caspase-3 staining as a marker of cell apoptosis and quantification of KPC cells positive for cleaved caspase-3 (ratio normalized to control) in organotypic matrices after 72 hours of treatment with Gem/Abraxane. Results are means ± SEM. *n* = 3 biological repeats with three matrices per condition and per repeat. *P* values were determined by nonparametric analysis of variance (ANOVA) test with Holm-Sidak correction for multiple comparisons.

biosensor did not affect KPC cell response to Gem/Abraxane (fig. S2J). Next, monitoring changes in CDK1 activity upon treatment with Gem/Abraxane demonstrated a decrease of lifetime and increased activation of CDK1 compared to control (Fig. 3B). This aligned with CDK1 activation and mitotic arrest as confirmed by FACS (fluorescence-activated cell sorting) and Western blot analyses (fig. S2, K and L) (49). After validating the CDK1 biosensor, we monitored individual


KPC cell response to chemotherapy within a 3D microenvironment (Fig. 3C).

Priming with Fasudil improves the spatiotemporal response of Gem/Abraxane in organotypic matrices

Cancer progression and response to drug treatment can be regulated by environmental cues within tumor subpopulations, such as areas of

Fig. 3. Spatiotemporal analyses of combination therapy are performed using the CDK1 biosensor.

(A) Schematic representation of the CDK1-FRET biosensor conformation upon activation and inactivation of CDK1 (23). PLK, Polo-like kinase; PBD, Polo-box domain; ATP, adenosine 5'-triphosphate; YFP, yellow fluorescent protein; MP, multiphoton. (B) Representative mCerulean lifetime maps, quantification of mCerulean lifetimes, and stratification of CDK1 activity in KPC cells upon treatment with Gem/Abraxane for 24 hours in 2D settings. $n = 3$ independent biological repeats with one technical replicate per repeat. (C) Representative intensity images and mCerulean lifetime maps of KPC-CDK1 cells imaged invading in organotypic matrices. (D) Monitoring of CDK1 activity in cells on top of the collagen matrix and in response to Gem/Abraxane over time. Representative mCerulean lifetime maps (top), quantification of mCerulean lifetimes (bottom, left) (60 cells per group represented), and CDK1 accumulation over time (bottom, right) (average of three matrices represented) in KPC cells seeded on top of primed (orange) and unprimed (purple) matrices. $n = 3$ independent matrices, >60 cells per group. (E) Monitoring of CDK1 activity in cells invading at depth into collagen matrix and in response to Gem/Abraxane over time. Representative mCerulean lifetime maps (top), quantification of mCerulean lifetimes (bottom, left) (60 cells per group represented), and CDK1 accumulation over time (bottom, right) (average of three matrices represented) in KPC cells invading into primed (orange) and unprimed (purple) matrices. $n = 3$ independent matrices, >40 cells per group. Results are means \pm SEM. P values were determined by unpaired, nonparametric t test with Mann-Whitney U correction.



Downloaded from <http://stm.sciencemag.org/> on April 5, 2017

invasion (50–53). Hence, we assessed CDK1 activity in cells invading into the matrix versus cells on top of the matrix over time (Fig. 3, C to E, and movie S4). For cells on top of the matrix, we observed a decrease in FRET lifetime and corresponding activation of CDK1 after 16 hours

of treatment with Gem/Abraxane. This was sustained for 24 hours and then reverted to higher lifetimes at 48 hours (Fig. 3D, purple line). An earlier activation of CDK1 in matrices that had been primed with Fasudil was evident after 8 hours of Gem/Abraxane treatment, and the

activation of CDK1 was prolonged (Fig. 3D, orange line). Monitoring of CDK1 at depth demonstrated a distinctly delayed pattern of response to Gem/Abraxane in invading cells (compare the purple line in Fig. 3D to that in Fig. 3E); however, Fasudil priming increased the response of invasive cells at later time points compared to Gem/Abraxane treatment alone (Fig. 3E). The ability to detect differences in drug efficacy in a spatial manner allowed us to uncover that proliferating cells on top of the matrix respond well to Gem/Abraxane therapy alone, whereas invading and less proliferative cells (confirmed in fig. S2M) (50) are less susceptible to cytotoxic drugs. Thus, although Fasudil interference with stroma-tumor feedback improves targeting of cells on top of the matrix, it may also have additional, yet somewhat delayed, benefits by rendering invasive cells more vulnerable to chemotherapy.

Priming live primary tumors enhances Gem/Abraxane efficacy

We next generated subcutaneous KPC-CDK1 xenografts, and once primary tumors were palpable, mice were primed with Fasudil for 3 days before treatment with Gem/Abraxane (Fig. 4A). Twenty-four hours after administration of Gem/Abraxane, live tumor tissues were exposed using a skin flap technique for intravital imaging (Fig. 4B). SHG imaging and polarized light microscopy of picosirius red staining of KPC xenografts confirmed that Fasudil priming reduces fibrillar collagen organization in this setting, whereas no significant change in collagen content was observed (Fig. 4, C and D; fig. S3, A and B; and movie S5). In vivo FLIM-FRET analysis of the CDK1-FRET biosensor (movie S6) demonstrated activation of CDK1 upon Gem/Abraxane treatment alone, which was enhanced in Fasudil-primed conditions (Fig. 4E, green bar versus blue bar), in line with findings in organotypic matrices (Figs. 2 and 3). Fasudil priming alone had no significant effect on CDK1 activity in live tumors (Fig. 4E, black bar versus orange bar). IHC analyses of pMYPT1 in KPC xenografts confirmed inhibition of ROCK signaling upon Fasudil priming (fig. S3C), whereas Ki67 and cleaved caspase-3 analyses confirmed that although Fasudil priming alone had no significant effect on cell proliferation or survival, it improved the effectiveness of Gem/Abraxane in this setting (fig. S3, D and E). To assess whether ECM-independent mechanisms may also play a role in the enhanced response to chemotherapy, we examined the known role of Fasudil as a vasodilator in vivo (28) by evaluating vasculature abundance using anti-CD31 staining. This demonstrated an increase in CD31-positive cells upon treatment with Fasudil (Fig. 4F). We next injected quantum dots into mice bearing subcutaneous KPC tumors to assess whether vascular patency was altered in Fasudil-treated conditions (39, 54). Here, an increase in quantum dot signal was observed outside blood vessels, with quantum dots leaking into the tumor tissue in Fasudil-primed conditions compared to control (Fig. 4, G and H, and movie S7). Because PC patients often present with locally invasive and metastatic disease at diagnosis (55), we next investigated whether Fasudil priming alone or in combination with chemotherapy alters metastatic colonization of secondary sites.

Priming with Fasudil enhances chemotherapy response at secondary sites and reduces metastatic spread

To mimic systemic ROCK inhibition or adjuvant therapy in the presence of circulating tumor cells, we performed intrasplenic injections of KPC cells expressing the CDK1-FRET biosensor in parallel with Fasudil administration (Fig. 5, A and B, and movie S8). FLIM-FRET measurements of the CDK1 biosensor in liver metastases revealed that priming with Fasudil enhanced Gem/Abraxane efficacy at this secondary site (Fig. 5, C to E). In line with our results in primary tumors (Fig. 4),

we observed enhanced CD31 staining and increased number of microvessels with detectable lumens in the livers of Fasudil-treated mice (Fig. 5F and fig. S4A), which could partly explain the observed enhanced drug response. Pathological and IHC analyses on serial sections of metastases (Fig. 5, G and H) confirmed that mice treated with Fasudil and Gem/Abraxane showed a marked reduction in metastatic spread compared to Gem/Abraxane treatment alone. This is in line with recent work regarding the establishment of the metastatic niche (56, 57) and prompted us to assess micrometastatic events, such as cancer cell extravasation, adhesion, response to shear stress, and colonization after Fasudil priming.

Priming hinders extravasation and spread in the liver while sensitizing cells to shear stress and reducing anchorage-independent growth

To identify pancreatic tumor cells that had recently extravasated in the liver and breached the matrix surrounding blood vessels, we stained liver tissues with Elastica van Gieson and PDX-1 (Fig. 6, A and B). Quantification of extravasation events revealed that priming with Fasudil impaired extravasation compared to control and Gem/Abraxane treatment (Fig. 6, A to C), suggesting that Fasudil may act as a potential anti-adhesion drug. This mirrors recent work showing that targeting early “homing” events in the liver using anti-adhesion drugs can have additional advantages over cytotoxic targeting alone (58, 59). To address the anti-adhesion effect of Fasudil in a more controlled platform, we used cell-derived matrices (CDMs) (60, 61). Here, priming with Fasudil during ECM deposition and remodeling reduced ECM integrity (fig. S4, B to D). KPC cells were then seeded onto CDMs in the presence or absence of Gem/Abraxane (Fig. 6, D and E), and time-lapse tracking (fig. S4E) revealed a marked reduction in KPC cell adhesion in Fasudil-primed conditions over time compared to control and Gem/Abraxane counterparts (Fig. 6E, compare black and orange lines). In addition, the cytotoxic effects of Gem/Abraxane combined with Fasudil’s anti-adhesion effect increased the reduction in KPC attachment and viability (Fig. 6E, compare green to blue lines at 24 hours). This was in line with FLIM-FRET analysis of CDK1 on CDMs and in the liver in vivo (Fig. 5C and fig. S4F), where Fasudil priming enhanced response to Gem/Abraxane.


To further assess the observed reduction of liver colonization upon Fasudil priming, we examined the viability of cells in response to shear stress and anchorage-independent growth (AIG), which circulating tumor cells are subjected to in vivo. KPC cells were primed with Fasudil and exposed to controlled shear stress as previously described (Fig. 6F) (62) and then plated on CDMs to measure their ability to attach, survive, or proliferate after shear stress. Cell attachment on CDMs and cell growth were reduced upon treatment with Fasudil, with a concomitant increase in apoptosis (Fig. 6G), as confirmed by FACS analyses (Fig. 6H). These data, along with reduced long-term AIG in Fasudil-primed conditions (Fig. 6I), point to a role of ROCK inhibition in sensitizing cells to shear stress in the systemic circulation and suggest an additional way in which Fasudil can impinge on metastasis in PC (10, 13, 63, 64).

Fasudil priming reduces cell streaming and metastatic niche remodeling

To assess whether priming with Fasudil affects KPC cell movement, we performed time-lapse monitoring of KPC cell streaming on CDMs primed with or without Fasudil and quantified cell movement anisotropy as a readout of coordinated cell movement (Fig. 7A and movie S9) (65). In control conditions, concerted streams of cells moving in a coordinated, organized manner were observed (Fig. 7A, green arrows)

Fig. 4. Priming live primary tumors enhances Gem/Abraxane efficacy.

(A) Schematic representation of subcutaneous injection of KPC cells, tumor development, and treatment timeline. IP, intraperitoneal; QD, quantum dots. **(B)** Schematic of intravital imaging of subcutaneous KPC-CDK1 xenografts using a skin flap technique. **(C)** Representative maximum intensity projections of ex vivo SHG imaging of tumor tissue and quantification of SHG signal acquired in subcutaneous KPC xenografts upon treatment with control (saline); Gem/Abraxane alone; Fasudil, then Gem/Abraxane; and Fasudil alone. *n* = 5 mice per group and five fields of view (FOVs) per mouse. **(D)** Left: Picrosirius red staining and polarized light imaging of tumor tissue. Right: Quantification of total signal (black) and contribution to signal emitted from collagen fibers with high (red), medium (yellow), and low (green) birefringence acquired via polarized light imaging. *n* = 5 mice per group and five FOVs per mouse. **(E)** Representative mCerulean lifetime maps, quantification of mCerulean lifetimes, and CDK1 activity in subcutaneous KPC-CDK1 tumors upon treatment with control (saline); Gem/Abraxane alone; Fasudil, then Gem/Abraxane; and Fasudil alone. *n* = 5 mice per group, 80 cells per mouse, and three regions of interest (ROIs) per cell. **(F)** CD31 staining and quantification of area positively stained in subcutaneous KPC-CDK1 tumors upon treatment with control (saline); Gem/Abraxane alone; Fasudil, then Gem/Abraxane; and Fasudil alone. *n* = 5 mice per group and five FOVs per mouse. **(G)** Intravital imaging of quantum dots (655 nm) circulating through tumor-associated blood vessels and diffusing into tumor tissue. **(H)** Quantification of quantum dot (Qdot) diffusion in subcutaneous KPC tumors upon treatment with control (saline) or Fasudil. *n* = 3 mice per group and 10 FOVs per mouse. Results are means ± SEM. *P* values were determined by nonparametric ANOVA test with Holm-Sidak correction for multiple comparisons and by unpaired, nonparametric *t* test with Mann-Whitney *U* correction for comparisons between two groups.



(65, 66). This was reduced in cells seeded on Fasudil-primed matrices, where noncoordinated cell movement was evident over time (Fig. 7, A and B), and was further supported by a clear decrease in cell stream

width compared to control (Fig. 7C). We next studied whether Fasudil priming altered metastatic spread patterns in the liver using IHC analysis of PDX-1-stained serial sections. Here, we observed different





Fig. 5. Priming with Fasudil improves chemotherapy at secondary sites and decreases metastatic burden. (A) Schematic representation of intrasplenic injection of KPC cells and treatment timeline. (B) Representative pictures of macrometastases (diameter, >200 μm) and micrometastases (diameter, <200 μm) identified via live imaging in liver metastases at the experimental end point. White dashed lines delimitate macrometastases and micrometastases. (C) Representative mCerulean lifetime maps in liver metastases. (D) Quantification of mCerulean lifetime. (E) CDK1 activity in metastatic KPC cells upon treatment with control (saline); Gem/Abraxane alone; Fasudil, then Gem/Abraxane; and Fasudil alone. $n = 4$ mice per group, 80 cells per mouse, three ROIs per cell. (F) CD31 staining and quantification of area positively stained and microvessel density in liver tissue upon treatment with control (saline); Gem/Abraxane alone; Fasudil, then Gem/Abraxane; and Fasudil alone. $n = 4$ mice per group and five FOVs per mouse. (G) Pathological examination of liver metastases and quantification of visible metastases on the surface of the tissue. White arrows point at KPC metastases visible at the surface of the organ. (H) Quantification of liver macrometastases normalized to liver surface area in hematoxylin and eosin (H&E) serial sections. Black arrows point at macrometastases in the liver tissue. Results are means \pm SEM. $n = 4$ mice per group and five serial sections per organ (100- μm step). P values were determined by nonparametric ANOVA test with Holm-Sidak correction for multiple comparisons.

morphology of metastases upon priming with Fasudil. In control and Gem/Abraxane conditions, we identified elongated and malleable emboli of KPC cells spreading throughout the liver tissue [Fig. 7, D (top) and E], whereas in Fasudil and Gem/Abraxane or Fasudil alone conditions, metastases were round, and elongated emboli were ablated [Fig. 7, D (top) and E]. This observation suggests that Fasudil priming

and manipulation of the ECM during the early stages of metastatic colonization (59) alter spread in the host tissue, as evidenced by an overall reduction in metastatic burden in these conditions (Fig. 5, G and H).

ECM remodeling can also provide cancer cells with a “fibrotic refuge” (67), supporting tumor growth and limiting chemotherapeutic targeting (68). Because Fasudil priming improved Gem/Abraxane

Fig. 6. Priming with Fasudil decreases KPC cell extravasation and adhesion in secondary sites and makes KPC cells more sensitive to shear stress. (A) Representative images of Elastica van Gieson (marker of vessel-associated collagen fibers) staining and PDX-1 (marker of PC cells) IHC staining in liver tissues after treatment with control (saline); Gem/Abraxane alone; Fasudil, then Gem/Abraxane; and Fasudil alone. BV, blood vessel; M, metastasis. Scale bars, 100 μ m. (B) Schematic representation of KPC cells that breached through the matrix surrounding blood vessels observed in liver tissue. (C) Quantification of KPC extravasation in the liver upon treatment with control (saline); Gem/Abraxane alone; Fasudil, then Gem/Abraxane; and Fasudil alone. $n = 4$ mice per group and five serial sections per mouse (100- μ m step). (D) Representative phase images of KPC cells 24 hours after seeding onto CDMs primed or unprimed with Fasudil and treated with or without Gem/Abraxane. (E) Automated quantification of KPC cell attachment to CDMs over time. $n = 3$ biological repeats with three CDMs per condition and per repeat and five FOVs per CDM. (F) Schematic representation of fluid shear stress assay, adapted from (63). (G) Quantification of cell attachment onto CDMs, growth, and apoptosis after shear stress for KPC cells \pm Fasudil pretreatment. P0, cells not subjected to shear stress; P5, cells subjected to five consecutive exposures to shear stress. Y-axis values (P5/P0 ratios) are values for cells subjected




to five exposures to shear stress divided by values for cells not exposed to shear stress. $n = 3$ biological repeats with one CDM per condition and per repeat. (H) FACS analysis of annexin and propidium iodide (PI) amounts in KPC cells 24 hours after shear stress. Representative FACS plots for one of the replicates of five replicates with means \pm SEM (bottom). Annexin V-positive population was defined as FITC⁺ (fluorescein isothiocyanate-positive)/PI⁻ (red gate), and all dead cells were defined as FITC⁺ and/or PI⁺ (blue gate). (I) Schematic representation of treatment timeline for AIG assay with representative images and quantification of AIG of KPC cells cultured \pm Fasudil and \pm Gem/Abraxane. $n = 3$ biological repeats with three wells per condition and per repeat. Results are means \pm SEM. P values were determined by unpaired, nonparametric t test with Mann-Whitney U correction (comparison between two groups) and nonparametric ANOVA test with Holm-Sidak correction for multiple comparisons.

effectiveness in the liver (Fig. 5, C to E), we assessed the ability of KPC cells to remodel the ECM upon priming with Fasudil. Using CDMs as a model system, we found that KPC cells can remodel the

matrix of unprimed CDMs, as measured by increased SHG signal over time (Fig. 7, F and G, black lines). This was impaired for KPC cells seeded on Fasudil-primed CDMs, where SHG intensity did not

Fig. 7. Priming with Fasudil impairs metastatic spread and remodeling of secondary sites.

(A) Representative images of KPC cell streams on CDMs primed with control or with Fasudil 62 hours after seeding. (i) Phase image, (ii) cell shape mask, and (iii) inset with arrows showing cell stream directionality. (B) Quantification of KPC cell movement anisotropy over time using FibrilTool (65). (C) Cell stream width 62 hours after seeding on CDMs. $n = 3$ biological repeats with three CDMs per condition and per repeat. (D) Representative images of PDX-1 staining, identifying different morphologies of metastatic emboli upon treatment with control (saline); Gem/Abraxane; Fasudil, then Gem/Abraxane; or Fasudil alone. Black arrowheads point at lines of KPC cells. Green dashed lines delimit individual metastases. (E) Schematic representation of lines of KPC cells observed by IHC analysis in the liver (top) and quantification of the number of lines on serial sections upon treatment with control (saline); Gem/Abraxane; Fasudil, then Gem/Abraxane; or Fasudil alone. $n = 4$ mice and five serial sections per mouse (100- μ m step). (F) Representative maximum projection of SHG imaging. (G) Quantification of SHG signal derived from primed (blue lines) or unprimed (black lines) CDMs before seeding KPC cells (thin lines) and 48 hours after seeding KPC cells (bold lines). $n = 3$ independent biological repeats with one CDM per condition and per repeat. (H) Representative maximum intensity projections of SHG imaging. (I) Quantification of SHG signal intensity in host liver tissue upon treatment with control (saline); Gem/Abraxane; Fasudil, then Gem/Abraxane; or Fasudil alone. $n = 4$ mice per group and five FOVs per mouse. (J) Representative maximum intensity projections of SHG imaging. (K) Quantification of SHG signal intensity in liver metastases upon treatment with control (saline); Gem/Abraxane; Fasudil, then Gem/Abraxane; or Fasudil alone. $n = 4$ mice per group and five FOVs per mouse. Results are means \pm SEM. P values were determined by unpaired, nonparametric t test with Mann-Whitney U correction (comparison between two groups) and nonparametric ANOVA test with Holm-Sidak correction for multiple comparisons.



significantly increase after seeding of KPC cells (Fig. 7, F and G, blue lines). Moreover, KPC cell protrusions on primed CDMs were also disrupted compared to control (fig. S4, G to I), in line with earlier observations, and this prompted us to assess the amount of fibrillar collagen within liver metastases. Here, we found that remodeling of the metastatic niche was impaired upon priming with Fasudil (Fig. 7, H to K, and fig. S4J). Hence, priming may make secondary tissues less permissive to the establishment of metastases and expose cancer cells to a less favorable environment (67). This may partly explain the enhanced response to chemotherapy at secondary sites observed in Fasudil-primed conditions.

Disruption of SRC signaling and actomyosin cytoskeleton dynamics with Fasudil may sensitize KPC cells to chemotherapy

In line with the reported role of ECM-integrin outside-in signaling in cancer (47, 69), we assessed whether the integrin-SRC signaling axis is altered upon priming with Fasudil. Using a SRC-FRET biosensor (fig. S5A) (70) in 3D organotypic matrices, we found that SRC activity is reduced after manipulation of the ECM with Fasudil (fig. S5, B and C) (70). Intravital imaging in subcutaneous KPC tumors also confirmed inhibition of SRC signaling in response to Fasudil priming in vivo (fig. S5, D and E). This is in line with the recent role that SRC has been proposed to play in both sensitizing cancer cells to chemotherapy (71–74) and driving ECM-dependent events in PC (75–77). Additionally, ROCK inhibitors can induce mitotic defects (78–81), and we therefore assessed early-to-mid and late mitosis in KPC subcutaneous tumors. This revealed that although we do not see any significant change of cell proliferation or death upon Fasudil priming (Fig. 4E and fig. S3, D and E), ROCK inhibition induces an accumulation of cells in late mitosis and multinuclear cells (fig. S5, F and G), thereby potentially making cells more responsive to subsequent treatment with antimicrotubule chemotherapy. Together, our data in cells from the KPC model suggest that priming delays PC progression in both primary and secondary sites. We therefore sought to translate our findings to patient-derived tumors.

Patient-derived models reveal potential for tailored, short-term priming strategy in PC

Because PC is highly heterogeneous (29, 82), we next assessed whether fibrillar collagen abundance could influence tumor response to priming with Fasudil before chemotherapy. SHG analysis of PDX samples from the APGI cohort (29) allowed us to identify TKCC2 as an example of a “low ECM PDX” and TKCC5 as an example of a “high ECM PDX” (Fig. 8A). Patient-derived cancer cell lines (PDCLs) isolated from the respective PDXs (29) were then subcutaneously re injected into mice (Fig. 8B). Subsequent SHG imaging revealed that re injected PDCLs recapitulated many of the original features of the collagen matrix (Fig. 8B), demonstrating the capacity of PDCLs to remodel the tissue and to “activate” host fibroblasts to maintain inherent features of the tumor.

To assess PDCL response to the priming regimen, we first established patient-personalized organotypic matrices, where cancer-associated fibroblasts (CAFs), “activated” by the respective patient-derived tumor cells in vivo, were isolated from PDXs, embedded in collagen, and characterized by IHC staining with pancytokeratin, α -smooth muscle actin, and fibroblast activation protein (figs. S6 and S7). After remodeling of the matrix by CAFs, matched patient-derived cancer cells were seeded on top of the contracted matrices (figs. S6, A and C, and S7, A and C), as previously performed with KPC cells (Figs. 2 and 3). Priming with Fasudil impaired the ability of the “high ECM” TKCC5 CAFs to remodel collagen, as demonstrated by SHG analysis (fig. S6, B and D to F), and

resulted in decreased cancer cell invasion (fig. S6, G and H) and increased response to Gem/Abraxane treatment (fig. S6, I and J). Conversely, priming had no effect on “low ECM” TKCC2 CAF-driven collagen contraction (fig. S7, B and D to F) and did not modify response to chemotherapy (fig. S7, G and H). This prompted us to assess TKCC2 and TKCC5 response to priming with Fasudil in live tumors.

PDCLs were engineered to express the CDK1-FRET biosensor, and in vitro FLIM-FRET measurements confirmed that the biosensor can distinguish changes in CDK1 activity in both lines (figs. S6, K and L, and S7, I and J), as previously achieved with KPC cells (fig. S2). CDK1-PDCLs were subcutaneously injected into mice, and when tumors were fully established (average tumor volume, 180 mm³, as previously described for KPC tumors; figs. S6M and S7K), mice were subjected to 3 days of priming with Fasudil before administration of Gem/Abraxane and intravital imaging (figs. S6M and S7K, timelines). Although SHG analysis demonstrated a reduction of fibrillar collagen abundance in the high ECM TKCC5 upon manipulation with Fasudil (Fig. 8C), priming had no effect on the matrix of low ECM TKCC2 (Fig. 8C). Intravital analysis of CDK1 activity in response to chemotherapy revealed that priming with Fasudil induces a robust increase of TKCC5 response to Gem/Abraxane in vivo (Fig. 8D, left). A moderate improvement of TKCC2 response to chemotherapy was observed (Fig. 8D, right), demonstrating a graded response to the priming strategy in relation to initial PDX collagen status (Fig. 8E).

Last, given the enhanced response to priming found in the high ECM TKCC5 model, we assessed the long-term effects of priming on therapeutic response in an orthotopic patient-derived model. Orthotopic injections of TKCC5 cells were conducted, and primary tumors were allowed to grow until average in vivo imaging system (IVIS) luciferase signal reached 5×10^7 photons/s (fig. S8A). Mice were subjected to cycles of priming with Fasudil before administration of Gem/Abraxane until the experimental end point (Fig. 8F and fig. S8A). Survival was increased by the priming regimen compared to treatment with Gem/Abraxane alone (mean survival: Gem/Abraxane, 51 days; Fasudil priming and Gem/Abraxane, 75 days) (Fig. 8F). Mice receiving Fasudil priming before Gem/Abraxane also had a reduced primary tumor burden at the ethical end point (fig. S8B). Time to detection of metastasis observed via whole-body IVIS imaging was also delayed by the priming regimen compared to control (fig. S8, A and C).

Finally, we created an in-house automated SHG tool to analyze the International Cancer Genome Consortium (ICGC) cohort of patient biopsy samples (231 ICGC samples) (Fig. 8G and fig. S8, D and E). Although we found no significant differences in survival or clinicopathological variables with regard to bulk patient ECM content (fig. S8F), in line with recent work (10), this rapid and label-free biopsy imaging approach could be used as a companion personalized biomarker for current stromal-based combination therapies in PC, where the initial amount of tumor ECM could guide whether a patient would be suitable for “transient” stromal intervention (Fig. 8, D to F) (12, 83).


DISCUSSION

Combined therapies and multimodal targeting have improved outcomes in multiple cancers (84), but little is known on how to streamline these methods to provide maximum benefit. Here, we demonstrate that transient priming of primary and secondary sites via ROCK inhibition improves chemotherapy efficacy and retards the onset of metastasis in PC.

Mechanoreciprocity and host tissue properties play a vital role in nascent tumors, from providing initial survival signals to driving cancer

Fig. 8. ECM-stratified patient-derived tumors respond in a graded manner to priming strategy.

(A) Schematic representation of PDX establishment and representative maximum projections of SHG imaging in high ECM and low ECM PDXs from the APCI PDX cohort. $n = 3$ cores per group. **(B)** Patient-derived cancer cell lines were isolated from PDXs, purified, and re-injected subcutaneously into non-obese diabetic–severe combined immunodeficient mice. Representative maximum intensity projections of SHG imaging and quantification of high ECM and low ECM PDCL xenografts. $n = 3$ tumors per group. **(C)** Representative maximum intensity projections of ex vivo SHG imaging in subcutaneous TKCC5 (left) and TKCC2 (right) xenografts upon treatment with control (saline), Gem/Abraxane, Fasudil and Gem/Abraxane, or Fasudil alone. **(D)** Representative images and quantification of in vivo measurements of mCerulean lifetime and CDK1 activity in subcutaneous TKCC5 (left) and TKCC2 (right) xenografts upon treatment with control (saline), Gem/Abraxane, Fasudil and Gem/Abraxane, or Fasudil alone. **(E)** Graded response to priming before Gem/Abraxane compared to Gem/Abraxane alone in TKCC2 and TKCC5 xenografts. Results are means \pm SEM. TKCC2: $n = 5$ mice per group; TKCC5: $n = 4$ for control, $n = 4$ for Gem/Abraxane, $n = 4$ for Fasudil, then Gem/Abraxane, $n = 3$ for priming with Fasudil. For SHG analysis, five FOVs per mouse were imaged; for FLIM-FRET analysis, 80 cells per mouse with three ROIs per cell were quantified. **(F)** Representative schematic of orthotopic injection of TKCC5-luciferase cells and treatment cycle. Kaplan-Meier analysis of survival for mice orthotopically injected with TKCC5 cancer cells and undergoing treatment cycles with control (saline); Gem/Abraxane; Fasudil, then Gem/Abraxane; and Fasudil alone. Control, $n = 10$ mice; Fasudil priming alone, $n = 9$ mice; Gem/Abraxane, $n = 9$ mice; Fasudil, then Gem/Abraxane, $n = 7$ mice. **(G)** Schematic representation of in-house automated SHG analysis of the ECM in the ICGC human tissue microarray (TMA) cohort, with examples of SHG signal in cores (triplicates) from patients with high, medium, and low SHG signal. Results are means \pm SEM. P values were determined by unpaired, nonparametric t test with Mann-Whitney U correction (comparison between two groups) and nonparametric ANOVA test with Holm-Sidak correction for multiple comparisons.



Downloaded from <http://stm.sciencemag.org/> on April 5, 2017

cell proliferation, invasion, and metastasis (85, 86). Here, we use a combination of 3D *in vitro* and *in vivo* platforms with mouse- and patient-derived PC cells to guide and optimize tissue manipulation scheduling in the context of Gem/Abraxane therapy. Our results suggest that short-term inhibition of cellular tension in the whole tumor tissue before chemotherapy reduces cancer progression and improves response to treatment. Despite the distinct composition of the ECM in our different *in vitro* and *in vivo* models, our data reveal a similar effect in all settings, suggesting that this is a general phenomenon for multiple microenvironments. This suggests that depriving cancer cells of cues provided by the surrounding matrix at both primary and secondary sites renders them more sensitive to cytotoxic drugs, partly via impaired integrin signaling, as previously demonstrated in melanoma (67). This is in line with our recent findings that inhibition of collagen cross-linking via antibody-targeted therapy against lysyl oxidase in combination with Gem effectively impaired PC progression (12). ROCK inhibition also seems to induce accumulation of mitotic defects *in vivo*, potentially making cells more susceptible to subsequent chemotherapy (3).

The molecular fingerprint of human PC is highly heterogeneous (29, 82). High-throughput SHG analysis of the human ICGC cohort revealed heterogeneity in collagen profiles across patients. Using *intra-vital* monitoring of chemotherapy efficacy in patient-derived samples, we showed a graded response to Fasudil priming strategies relative to the initial fibrillar collagen profile in tissue biopsies. Our findings thereby suggest that high amounts of fibrillar collagen could potentially serve as a companion biomarker to identify patients who are likely to benefit from transient ECM manipulation before chemotherapy. This is in line with current clinical stroma-targeting therapies, where such companion biomarkers are being used for hyaluronic acid targeting, supporting matrix manipulation therapy in a subpopulation of patients (83). Fine-tuned ECM-based stratification could therefore facilitate a more tailored therapeutic approach to matrix manipulation therapy in PC and could be used as an alternative to the “all patients” chronic stromal targeting approach in this disease.

Although we demonstrate disruption of the physical properties of the ECM upon manipulation with Fasudil, we also reveal that repurposing Fasudil’s clinical vasodilatory effects (28) through transient priming before chemotherapy improves short-term tumor blood perfusion and, thereby, drug delivery. This is in line with its current use for the treatment of cerebral vasospasm after subarachnoid hemorrhage in Japan (87–89) while avoiding any long-term toxic effects that could arise from chronic treatment (36, 39). Therefore, targeting ECM-dependent and ECM-independent changes in cancer appears to be an important advantage of transient ROCK inhibition compared to chronic ECM targeting alone (39, 90, 91) and warrants further consideration with regard to repurposing the off-patent drugs in PC (92).

Monitoring the onset of hepatic micrometastasis revealed that manipulation of tissue at secondary sites impairs liver colonization. Analyses on CDMs and in the liver demonstrated that priming with Fasudil alters KPC cell attachment, coordinated movement, and malleable spread of the tumor emboli, potentially via changes of the mechanical and biochemical properties of the host ECM, thereby altering ECM-cell interactions and durotaxis (93, 94). Furthermore, the Rho-ROCK-LMK pathway drives path generation by leading tumor cells (66, 95), and hence, ROCK inhibition with Fasudil may inhibit path generation and coordinated cell movement of tumor cells in this context (95, 96). Additionally, priming with Fasudil may decrease cell survival in the bloodstream via impaired tolerance to shear stress (97). Whereas previous studies have reported conflicting findings on the effects of ROCK

inhibition on cell invasion (98–100), short-term treatment with Fasudil did not show adverse effects, unlike chronic ROCK targeting. We also reveal that Fasudil priming impairs the ability of metastasized cells to create a fibrotic refuge, potentially enhancing their vulnerability to subsequent chemotherapy (67). We propose that instead of completely ablating stroma–cancer cell feedback, transient priming of tissue by Fasudil before chemotherapy can impair cancer cell establishment, survival, growth, and spread at multiple sites *in vivo* while minimizing negative effects that may arise from chronic treatment.

Although Fasudil monotherapy or combinations with selected cardiovascular agents have previously been shown to be safe in humans by numerous large-scale studies (87–89), this agent is yet to be combined with chemotherapies in the clinic. A phase 1 clinical trial would determine the safety of transient “priming” regimen with Fasudil before treatment with Gem/Abraxane in patients. Our study used patient TMA material from the ICGC cohort (82), which is composed of largely early-stage tumors (I, IIa, and IIb) and hence does not equally cover the full spectrum of the disease. Validation studies would ideally include a cohort of more metastatic disease to fully appreciate the utility of our proposed SHG companion biomarker. Additionally, given the dual effects of Fasudil priming on both the ECM and the tumor vasculature, combination of both SHG and CD31-based biomarkers might further facilitate the identification of patients who could benefit from priming before chemotherapy.

Newer ROCK inhibitors such as K-115 (Ripasudil), which have recently entered the clinic for the treatment of glaucoma (101, 102) or are currently in the clinical testing pipeline, including phase 2 clinical trial for glaucoma (AMA0076) (103), or CCT129254 or AT13148, which reduce metastasis in other cancers (104), could also have similar applications (105). Patient presentation in PC ranges from early local invasion at the time of diagnosis to late metastatic disease (106). We have demonstrated multisite benefits using priming in combination with standard-of-care therapy (summarized in fig. S9) and envision its potential use to treat PC at several stages.

MATERIALS AND METHODS

Study design

This study interrogates the effect of transient manipulation of tissue tension via ROCK inhibition on PC progression and response to Gem/Abraxane. *In vitro* organotypic and CDM experiments were performed in independent biological triplicates, with three technical replicates per repeat and per treatment group. For *in vivo* experiments, numbers of mice used for each model are outlined in corresponding figures and figure legends. *In vivo* priming started when tumor volume reached 180 mm³ (average size) or 7 × 10⁵ photons/s (average IVIS signal). Mice for which tumor volume or IVIS signal was 10% lower or higher than the average value before enrollment were excluded from analysis.

FLIM-FRET analysis of CDK1 and SRC activity *in vitro* was conducted in >30 cells per group in three independent biological repeats. *In vivo* analysis of CDK1 and SRC was performed in 80 cells per mouse, with measurements in three subcellular areas per cell to generate an average value for CDK1 specifically, whereas measurements of lifetime in the whole cell (one value per cell) were performed for analysis of SRC activity.

IHC, SHG, picrosirius red, and GLCM analyses were conducted on three representative FOVs in organotypic matrices and CDMs and in five representative FOVs in subcutaneous xenograft and intrasplenic

experiments. Metastatic burden, extravasation, and metastasis morphology in the liver were analyzed in serial sections (five sections per organ with a 100- μ m step). Experimental end points for survival experiments were in compliance with Garvan Ethics Committee guidelines (13/17, 14/06, 14/11, and 16/13 protocols).

Statistical analysis

Unless stated otherwise, *P* values were determined by unpaired, non-parametric *t* test with Mann-Whitney *U* correction (comparison between two groups) or nonparametric ANOVA test with Holm-Sidak correction for multiple comparison (more than two groups). Kaplan-Meier curves were compared using a log-rank Mantel-Cox test. Exact *P* values for all figures are provided in table S1.

SUPPLEMENTARY MATERIALS

www.sciencetranslationalmedicine.org/cgi/content/full/9/384/eaai8504/DC1
Materials and Methods

Fig. S1. ROCK inhibition with Fasudil and Y-27632 impairs ECM integrity.

Fig. S2. The CDK1-FRET biosensor distinguishes changes in CDK1 activity and is a surrogate for cell cycle arrest.

Fig. S3. Priming with Fasudil disrupts ECM remodeling, inhibits ROCK signaling, and improves Gem/Abraxane efficacy in vivo.

Fig. S4. Priming with Fasudil influences liver vasculature, cell attachment to CDMs, response to chemotherapy, and remodeling of the ECM.

Fig. S5. Priming with Fasudil results in decreased SRC activity and defects in mitosis.

Fig. S6. High ECM TKCC5 patient model responds to priming strategies in a 3D patient-personalized organotypic matrix.

Fig. S7. Low ECM TKCC2 patient model does not respond to priming strategies in a 3D patient-personalized organotypic matrix.

Fig. S8. TKCC5 orthotopic tumors respond to priming, and SHG does not predict survival.

Fig. S9. Priming with Fasudil uncouples PC progression.

Table S1. List of *P* values.

Table S2. Details of antibodies used for the study.

Movie S1. 4D monitoring of fibroblast-ECM interactions upon treatment with vehicle and Fasudil.

Movie S2. Live FLIM-FRET imaging of the CDK1 biosensor in KPC cells in response to Abraxane and Abraxane + RO3306.

Movie S3. Live FLIM-FRET imaging of the CDK1 biosensor in KPC cells in interphase and mitosis.

Movie S4. Live FLIM-FRET monitoring of CDK1 activity in KPC cells actively interacting with an organotypic matrix.

Movie S5. Intravital FLIM-FRET imaging of subcutaneous xenografts with KPC-CDK1 cells and imaging of fibrillar collagen.

Movie S6. Intravital monitoring of CDK1 accumulation in subcutaneous KPC tumors.

Movie S7. Intravital imaging of quantum dots circulating through tumor-associated vasculature and diffusing into tumor tissue upon priming with Fasudil.

Movie S8. Imaging of liver tissue with metastatic KPC cells expressing the CDK1 biosensor forming macrometastases and micrometastases.

Movie S9. Time-lapse tracking of collective cell streaming on CDMs unprimed or primed with Fasudil.

Reference (107)

REFERENCES AND NOTES

1. D. Goldstein, R. H. El-Maraghi, P. Hammel, V. Heinemann, V. Kunzmann, J. Sastre, W. Scheithauer, S. Siena, J. Tabernero, L. Teixeira, G. Tortora, J.-L. Van Laethem, R. Young, D. N. Penenberg, B. Lu, A. Romano, D. D. Von Hoff, *nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: Long-term survival from a phase III trial*. *J. Natl. Cancer Inst.* **107**, dju413 (2015).
2. D. D. Von Hoff, T. Ervin, F. P. Arena, E. G. Chiorean, J. Infante, M. Moore, T. Seay, S. A. Tjulandin, W. W. Ma, M. N. Saleh, M. Harris, M. Reni, S. Dowden, D. Laheru, N. Bahary, R. K. Ramanathan, J. Tabernero, M. Hidalgo, D. Goldstein, E. Van Cutsem, X. Wei, J. Iglesias, M. F. Renschler, Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N. Engl. J. Med.* **369**, 1691–1703 (2013).
3. N. Rath, M. F. Olson, Rho-associated kinases in tumorigenesis: Re-considering ROCK inhibition for cancer therapy. *EMBO Rep.* **13**, 900–908 (2012).

4. V. Sanz-Moreno, C. Gaggioli, M. Yeo, J. Albrengues, F. Wallberg, A. Viros, S. Hooper, R. Mitter, C. C. F eral, M. Cook, J. Larkin, R. Marais, G. Meneguzzi, E. Sahai, C. J. Marshall, ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. *Cancer Cell* **20**, 229–245 (2011).
5. I. Rodr guez-Hernandez, G. Cantelli, F. Bruce, V. Sanz-Moreno, Rho, ROCK and actomyosin contractility in metastasis as drug targets. *FT000Res.* **5**, 783 (2016).
6. Y. Kagawa, S. Matsumoto, Y. Kamioka, K. Mimori, Y. Naito, T. Ishii, D. Okuzaki, N. Nishida, S. Maeda, A. Naito, J. Kikuta, K. Nishikawa, J. Nishimura, N. Haraguchi, I. Takemasa, T. Mizushima, M. Ikeda, H. Yamamoto, M. Sekimoto, H. Ishii, Y. Doki, M. Matsuda, A. Kikuchi, M. Mori, M. Ishii, Cell cycle-dependent Rho GTPase activity dynamically regulates cancer cell motility and invasion in vivo. *PLOS ONE* **8**, e83629 (2013).
7. M. J. Paszek, N. Zahir, K. R. Johnson, J. N. Lakin, G. I. Rozenberg, A. Gefen, C. A. Reinhart-King, S. S. Margulies, M. Dembo, D. Boettiger, D. A. Hammer, V. M. Weaver, Tensional homeostasis and the malignant phenotype. *Cancer Cell* **8**, 241–254 (2005).
8. A. Sadok, C. J. Marshall, Rho GTPases: Masters of cell migration. *Small GTPases* **5**, e29710 (2014).
9. M. S. Samuel, J. I. Lopez, E. J. McGhee, D. R. Croft, D. Strachan, P. Timpson, J. Munro, E. Schr der, J. Zhou, V. G. Brunton, N. Barker, H. Clevers, O. J. Sansom, K. I. Anderson, V. M. Weaver, M. F. Olson, Actomyosin-mediated cellular tension drives increased tissue stiffness and β -catenin activation to induce epidermal hyperplasia and tumor growth. *Cancer Cell* **19**, 776–791 (2011).
10. H. Laklai, Y. A. Miroshnikova, M. W. Pickup, E. A. Collisson, G. E. Kim, A. S. Barrett, R. C. Hill, J. N. Lakin, D. D. Schlaepfer, J. K. Mouw, V. S. LeBleu, N. Roy, S. V. Novitskiy, J. S. Johansen, V. Poli, R. Kalluri, C. A. Iacobuzio-Donahue, L. D. Wood, M. Hebrok, K. Hansen, H. L. Moses, V. M. Weaver, Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. *Nat. Med.* **22**, 497–505 (2016).
11. M. W. Pickup, J. K. Mouw, V. M. Weaver, The extracellular matrix modulates the hallmarks of cancer. *EMBO Rep.* **15**, 1243–1253 (2014).
12. B. W. Miller, J. P. Morton, M. Pinese, G. Saturno, N. B. Jamieson, E. McGhee, P. Timpson, J. Leach, L. McGarry, E. Shanks, P. Bailey, D. Chang, K. Oien, S. Karim, A. Au, C. Steele, C. R. Carter, C. McKay, K. Anderson, T. R. J. Evans, R. Marais, C. Springer, A. Biankin, J. T. Erler, O. J. Sansom, Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: Inhibition of LOX abrogates metastasis and enhances drug efficacy. *EMBO Mol. Med.* **7**, 1063–1076 (2015).
13. A. Johansson-Percival, Z.-J. Li, D. D. Lakhiani, B. He, X. Wang, J. Hamzah, R. Ganss, Intratumoral LIGHT restores pericyte contractile properties and vessel integrity. *Cell Rep.* **13**, 2687–2698 (2015).
14. F. Winkler, S. V. Kozin, R. T. Tong, S.-S. Chae, M. F. Booth, I. Garkavtsev, L. Xu, D. J. Hicklin, D. Fukumura, E. di Tomaso, L. L. Munn, R. K. Jain, Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. *Cancer Cell* **6**, 553–563 (2004).
15. S. I. J. Ellenbroek, J. van Rheenen, Imaging hallmarks of cancer in living mice. *Nat. Rev. Cancer* **14**, 406–418 (2014).
16. J. R. W. Conway, N. O. Carragher, P. Timpson, Developments in preclinical cancer imaging: Innovating the discovery of therapeutics. *Nat. Rev. Cancer* **14**, 314–328 (2014).
17. S. R. Hingorani, L. Wang, A. S. Multani, C. Combs, T. B. Deramaudt, R. H. Hruban, A. K. Rustgi, S. Chang, D. A. Tuveson, *Trp53^{R172H}* and *Kras^{G12D}* cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. *Cancer Cell* **7**, 469–483 (2005).
18. S. R. Hingorani, E. F. Petricoin III, A. Maitra, V. Rajapakse, C. King, M. A. Jacobetz, S. Ross, T. P. Conrads, T. D. Veenstra, B. A. Hitt, Y. Kawaguchi, D. Johann, L. A. Liotta, H. C. Crawford, M. E. Putt, T. Jacks, C. V. E. Wright, R. H. Hruban, A. M. Lowy, D. A. Tuveson, Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. *Cancer Cell* **4**, 437–450 (2003).
19. A. L. Kennedy, J. P. Morton, I. Manoharan, D. M. Nelson, N. B. Jamieson, J. S. Pawlikowski, T. McBryan, B. Doyle, C. McKay, K. A. Oien, G. H. Enders, R. Zhang, O. J. Sansom, P. D. Adams, Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. *Mol. Cell* **42**, 36–49 (2011).
20. S. Walz, F. Lorenzin, J. Morton, K. E. Wiese, B. von Eyss, S. Herold, L. Rycak, H. Dumay-Odelot, S. Karim, M. Bartkuhn, F. Roels, T. W stefeld, M. Fischer, M. Teichmann, L. Zender, C.-L. Wei, O. Sansom, E. Wolf, M. Eilers, Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. *Nature* **511**, 483–487 (2014).
21. D. C. Morran, J. Wu, N. B. Jamieson, A. Mrowinska, G. Kalna, S. A. Karim, A. Y. M. Au, C. K. Scarlett, D. K. Chang, M. Z. Pajak; Australian Pancreatic Cancer Genome Initiative, C. J. Oien, C. J. McKay, C. R. Carter, G. Gillen, S. Champion, S. L. Pimlott, K. I. Anderson, T. R. J. Evans, S. M. Grimmond, A. V. Biankin, O. J. Sansom, J. P. Morton, Targeting mTOR dependency in pancreatic cancer. *Gut* **63**, 1481–1489 (2014).
22. O. Gavet, J. Pines, Activation of cyclin B1-Cdk1 synchronizes events in the nucleus and the cytoplasm at mitosis. *J. Cell Biol.* **189**, 247–259 (2010).
23. O. Gavet, J. Pines, Progressive activation of CyclinB1-Cdk1 coordinates entry to mitosis. *Dev. Cell* **18**, 533–543 (2010).

24. M. E. Bekier, R. Fischbach, J. Lee, W. R. Taylor, Length of mitotic arrest induced by microtubule-stabilizing drugs determines cell death after mitotic exit. *Mol. Cancer Ther.* **8**, 1646–1654 (2009).
25. Z. Yang, A. E. Kenny, D. A. Brito, C. L. Rieder, Cells satisfy the mitotic checkpoint in Taxol, and do so faster in concentrations that stabilize syntelic attachments. *J. Cell Biol.* **186**, 675–684 (2009).
26. V. Magidson, J. He, J. G. Ault, C. B. O’Connell, N. Yang, I. Tikhonenko, B. F. McEwen, H. Sui, A. Khodjakov, Unattached kinetochores rather than intrakinetochores arrest mitosis in taxol-treated cells. *J. Cell Biol.* **212**, 307–319 (2016).
27. M. Castedo, J.-L. Perfettini, T. Roumier, G. Kroemer, Cyclin-dependent kinase-1: Linking apoptosis to cell cycle and mitotic catastrophe. *Cell Death Differ.* **9**, 1287–1293 (2002).
28. V. Gupta, N. Gupta, I. H. Shaik, R. Mehvar, I. F. McMurtry, M. Oka, E. Nozik-Grayck, M. Komatsu, F. Ahsan, Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension. *J. Control. Release* **167**, 189–199 (2013).
29. N. Waddell, M. Pajic, A.-M. Patch, D. K. Chang, K. S. Kassahn, P. Bailey, A. L. Johns, D. Miller, K. Nones, K. Quek, M. C. J. Quinn, A. J. Robertson, M. Z. H. Fadlullah, T. J. C. Bruxner, A. N. Christ, I. Harliwong, S. Idrisoglu, S. Manning, C. Nourse, E. Nourbakhsh, S. Wani, P. J. Wilson, E. Markham, N. Cloonan, M. J. Anderson, J. L. Fink, O. Holmes, S. H. Kazakoff, C. Leonard, F. Newell, B. Poudel, S. Song, D. Taylor, N. Waddell, S. Wood, Q. Xu, J. Wu, M. Pinese, M. J. Crowley, H. C. Lee, M. D. Jones, A. M. Nagrial, J. Humphris, L. A. Chantrill, V. Chin, A. M. Steinmann, A. Mawson, E. S. Humphrey, E. K. Colvin, A. Chou, C. J. Scarlett, A. V. Pinho, M. Giry-Laterriere, I. Rooman, J. S. Samra, J. G. Kench, J. A. Pettitt, N. D. Merrett, C. Toon, K. Epari, N. Q. Nguyen, A. Barbour, N. Zeps, N. B. Jamieson, J. S. Graham, S. P. Niclou, R. Bjerkvig, R. Grützmann, D. Aust, R. H. Hruban, A. Maitra, C. A. Iacobuzio-Donahue, C. L. Wolfgang, R. A. Morgan, R. T. Lawlor, V. Corbo, C. Bassi, M. Falconi, G. Zamboni, G. Tortora, M. A. Tempero; Australian Pancreatic Cancer Genome Initiative, A. J. Gill, J. R. Eshleman, C. Pilarsky, A. Scarpa, E. A. Musgrove, J. V. Pearson, A. V. Biankin, S. M. Grimmond, Whole genomes redefine the mutational landscape of pancreatic cancer. *Nature* **518**, 495–501 (2015).
30. M. F. Olson, E. Sahai, The actin cytoskeleton in cancer cell motility. *Clin. Exp. Metastasis* **26**, 273–287 (2009).
31. H. Marei, A. Carpy, A. Woroniuk, C. Vennin, G. White, P. Timpson, B. Macek, A. Malliri, Differential Rac1 signalling by guanine nucleotide exchange factors implicates FHL1 in regulating Rac1-driven cell migration. *Nat. Commun.* **7**, 10664 (2016).
32. T. R. Cox, D. Bird, A.-M. Baker, H. E. Barker, M. W.-Y. Ho, G. Lang, J. T. Erler, LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. *Cancer Res.* **73**, 1721–1732 (2013).
33. J. M. Rawlins, W. L. Lam, R. O. Karoo, I. L. Naylor, D. T. Sharpe, Quantifying collagen type in mature burn scars: A novel approach using histology and digital image analysis. *J. Burn Care Res.* **27**, 60–65 (2006).
34. J. Kular, K. G. Scheer, N. T. Pyne, A. H. Allam, A. N. Pollard, A. Magenau, R. L. Wright, N. Kolesnikoff, P. A. Moretti, L. Wullkopf, F. C. Stomski, A. J. Cowin, J. M. Woodcock, M. A. Grimbaldston, S. M. Pitson, P. Timpson, H. S. Ramshaw, A. F. Lopez, M. S. Samuel, A negative regulatory mechanism involving 14-3-3 ζ limits signaling downstream of ROCK to regulate tissue stiffness in epidermal homeostasis. *Dev. Cell* **35**, 759–774 (2015).
35. R. Cicchi, D. Kapsokalyvas, V. De Giorgi, V. Maio, A. Van Wiechen, D. Massi, T. Lotti, F. S. Pavone, Scoring of collagen organization in healthy and diseased human dermis by multiphoton microscopy. *J. Biophotonics* **3**, 34–43 (2010).
36. P. P. Provenzano, C. Cuevas, A. E. Chang, V. K. Goel, D. D. Von Hoff, S. R. Hingorani, Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. *Cancer Cell* **21**, 418–429 (2012).
37. A. Neesse, P. Michl, K. K. Frese, C. Feig, N. Cook, M. A. Jacobetz, M. P. Lolkema, M. Buchholz, K. P. Olive, T. M. Gress, D. A. Tuveson, Stromal biology and therapy in pancreatic cancer. *Gut* **60**, 861–868 (2011).
38. T. R. Cox, J. R. Erler, Fibrosis and cancer: Partner in crime or opposing forces? *Trends Cancer* **2**, 279–282 (2016).
39. M. A. Jacobetz, D. S. Chan, A. Neesse, T. E. Bapiro, N. Cook, K. K. Frese, C. Feig, T. Nakagawa, M. E. Caldwell, H. I. Zecchini, M. P. Lolkema, P. Jiang, A. Kultti, C. B. Thompson, D. C. Maneval, D. I. Jodrell, G. I. Frost, H. M. Shepard, J. N. Skepper, D. A. Tuveson, Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. *Gut* **62**, 112–120 (2013).
40. K. P. Olive, M. A. Jacobetz, C. J. Davidson, A. Gopinathan, D. McIntyre, D. Honess, B. Madhu, M. A. Goldgraben, M. E. Caldwell, D. Allard, K. K. Frese, G. DeNicola, C. Feig, C. Combs, S. P. Winter, H. Ireland-Zecchini, S. Reichelt, W. J. Howat, A. Chang, M. Dhara, L. Wang, F. Rückert, R. Grützmann, C. Pilarsky, K. Izeradjene, S. R. Hingorani, P. Huang, S. E. Davies, W. Plunkett, M. Egorin, R. H. Hruban, N. Whitebread, K. McGovern, J. Adams, C. Iacobuzio-Donahue, J. Griffiths, D. A. Tuveson, Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. *Science* **324**, 1457–1461 (2009).
41. A. D. Rhim, P. E. Oberstein, D. H. Thomas, E. T. Mirek, C. F. Palermo, S. A. Sastra, E. N. Dekleva, T. Saunders, C. P. Becerra, I. W. Tattersall, C. B. Westphalen, J. Kitajewski, M. G. Fernandez-Barrena, M. E. Fernandez-Zapico, C. Iacobuzio-Donahue, K. P. Olive, B. Z. Stanger, Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. *Cancer Cell* **25**, 735–747 (2014).
42. B. C. Özdemir, T. Pentcheva-Hoang, J. L. Carstens, X. Zheng, C.-C. Wu, T. R. Simpson, H. Laklai, H. Sugimoto, C. Kahlert, S. V. Novitskiy, A. De Jesus-Acosta, P. Sharma, P. Heidari, U. Mahmood, L. Chin, H. L. Moses, V. M. Weaver, A. Maitra, J. P. Allison, V. S. LeBleu, R. Kalluri, Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. *Cancer Cell* **25**, 719–734 (2014).
43. J. J. Lee, R. M. Perera, H. Wang, D.-C. Wu, X. S. Liu, S. Han, J. Fitamant, P. D. Jones, K. S. Ghanta, S. Kawano, J. M. Nagle, V. Deshpande, Y. Boucher, T. Kato, J. K. Chen, J. K. Willmann, N. Bardeesy, P. A. Beachy, Stromal response to Hedgehog signaling restrains pancreatic cancer progression. *Proc. Natl. Acad. Sci. U.S.A.* **111**, E3091–E3100 (2014).
44. J. P. Morton, P. Timpson, S. A. Karim, R. A. Ridgway, D. Athineos, B. Doyle, N. B. Jamieson, K. A. Oien, A. M. Lowy, V. G. Brunton, M. C. Frame, T. R. J. Evans, O. J. Sansom, Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 246–251 (2010).
45. Z. Erami, D. Herrmann, S. C. Warren, M. Nobis, E. J. McGhee, M. C. Lucas, W. Leung, N. Reischmann, A. Mrowinska, J. P. Schwarz, S. Kadir, J. R. W. Conway, C. Vennin, S. A. Karim, A. D. Campbell, D. Gallego-Ortega, A. Magenau, K. J. Murphy, R. A. Ridgway, A. M. Law, S. N. Walters, S. T. Grey, D. R. Croucher, L. Zhang, H. Herzog, E. C. Hardeman, P. W. Gunning, C. J. Ormandy, T. R. J. Evans, D. Strathee, O. J. Sansom, J. P. Morton, K. I. Anderson, P. Timpson, Intravital FRAP imaging using an E-cadherin-GFP mouse reveals disease- and drug-dependent dynamic regulation of cell-cell junctions in live tissue. *Cell Rep.* **14**, 152–167 (2016).
46. S. J. Ibbetson, N. T. Pyne, A. N. Pollard, M. F. Olson, M. S. Samuel, Mechanotransduction pathways promoting tumor progression are activated in invasive human squamous cell carcinoma. *Am. J. Pathol.* **183**, 930–937 (2013).
47. K. R. Levental, H. Yu, L. Kass, J. N. Lakins, M. Egeblad, J. T. Erler, S. F. T. Fong, K. Csizsar, A. Giaccia, W. Weninger, M. Yamauchi, D. L. Gasser, V. M. Weaver, Matrix crosslinking forces tumor progression by enhancing integrin signaling. *Cell* **139**, 891–906 (2009).
48. L. T. Vassilev, C. Tovar, S. Chen, D. Knezevic, X. Zhao, H. Sun, D. C. Heimbrook, L. Chen, Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. *Proc. Natl. Acad. Sci. U.S.A.* **103**, 10660–10665 (2006).
49. F. Hans, S. Dimitrov, Histone H3 phosphorylation and cell division. *Oncogene* **20**, 3021–3027 (2001).
50. S. Alexander, P. Friedl, Cancer invasion and resistance: Interconnected processes of disease progression and therapy failure. *Trends Mol. Med.* **18**, 13–26 (2012).
51. E. Sahai, C. J. Marshall, Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. *Nat. Cell Biol.* **5**, 711–719 (2003).
52. G. Charras, E. Sahai, Physical influences of the extracellular environment on cell migration. *Nat. Rev. Mol. Cell Biol.* **15**, 813–824 (2014).
53. P. Timpson, E. J. McGhee, J. P. Morton, A. von Kriegsheim, J. P. Schwarz, S. A. Karim, B. Doyle, J. A. Quinn, N. O. Carragher, M. Edward, M. F. Olson, M. C. Frame, V. G. Brunton, O. J. Sansom, K. I. Anderson, Spatial regulation of RhoA activity during pancreatic cancer cell invasion driven by mutant p53. *Cancer Res.* **71**, 747–757 (2011).
54. D. Gallego-Ortega, A. Ledger, D. L. Roden, A. M. K. Law, A. Magenau, Z. Kikhtyak, C. Cho, S. L. Allerdice, H. J. Lee, F. Valdes-Mora, D. Herrmann, R. Salomon, A. I. J. Young, B. Y. Lee, C. M. Sergio, W. Kaplan, C. Piggitt, J. R. W. Conway, B. Rabinovich, E. K. A. Millar, S. R. Oakes, T. Chtanova, A. Swarbrick, M. J. Naylor, S. O’Toole, A. R. Green, P. Timpson, J. M. W. Gee, I. O. Ellis, S. J. Clark, C. J. Ormandy, ELF5 drives lung metastasis in luminal breast cancer through recruitment of Gr1⁺ CD11b⁺ myeloid-derived suppressor cells. *PLoS Biol.* **13**, e1002330 (2015).
55. M. Hidalgo, Pancreatic cancer. *N. Engl. J. Med.* **362**, 1605–1617 (2010).
56. B. Costa-Silva, N. M. Aiello, A. J. Ocean, S. Singh, H. Zhang, B. K. Thakur, A. Becker, A. Hoshino, M. T. Mark, H. Molina, J. Xiang, T. Zhang, T.-M. Theilen, G. Garcia-Santos, C. Williams, Y. Araso, Y. Huang, G. Rodrigues, T.-L. Shen, K. J. Labori, I. M. B. Lothe, E. H. Kure, J. Hernandez, A. Dousot, S. H. Ebbesen, P. M. Grandgenett, M. A. Hollingsworth, M. Jain, K. Mallya, S. K. Batra, W. R. Jarnagin, R. E. Schwartz, I. Matei, H. Peinado, B. Z. Stanger, J. Bromberg, D. Lyden, Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. *Nat. Cell Biol.* **17**, 816–826 (2015).
57. A. Hoshino, B. Costa-Silva, T.-L. Shen, G. Rodrigues, A. Hashimoto, M. Tesic Mark, H. Molina, S. Kohsaka, A. Di Giannatale, S. Ceder, S. Singh, C. Williams, N. Sotop, K. Uryu, L. Parmer, T. King, L. Bojmar, A. E. Davies, Y. Araso, T. Zhang, H. Zhang, J. Hernandez, J. M. Weiss, V. D. Dumont-Cole, K. Kramer, L. H. Wexler, A. Narendran, G. K. Schwartz, J. H. Healey, P. Sandstrom, K. J. Labori, E. H. Kure, P. M. Grandgenett, M. A. Hollingsworth, M. de Sousa, S. Kaur, M. Jain, K. Mallya, S. K. Batra, W. R. Jarnagin, M. S. Brady, O. Fodstad, V. Muller, K. Pantel, A. J. Minn, M. J. Bissell, B. A. Garcia, Y. Kang, V. K. Rajasekhar, C. M. Ghajar, I. Matei, H. Peinado, J. Bromberg, D. Lyden, Tumour exosome integrins determine organotropic metastasis. *Nature* **527**, 329–335 (2015).

58. C. Manegold, J. Vansteenkiste, F. Cardenal, W. Schuetz, P. J. Woll, E. Ulsperger, A. Kerber, J. Eckmayr, J. von Pawel, Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer. *Invest. New Drugs* **31**, 175–182 (2013).
59. L. Ritsma, E. J. A. Steller, E. Beerling, C. J. M. Loomans, A. Zomer, C. Gerlach, N. Vrisekoop, D. Seinstra, L. van Gorp, R. Schäfer, D. A. Raats, A. de Graaff, T. N. Schumacher, E. J. P. de Koning, I. H. B. Rinkes, O. Kranenburg, J. van Rheenen, Intravital microscopy through an abdominal imaging window reveals a pre-micrometastasis stage during liver metastasis. *Sci. Transl. Med.* **4**, 158ra145 (2012).
60. E. Cukierman, R. Pankov, D. R. Stevens, K. M. Yamada, Taking cell-matrix adhesions to the third dimension. *Science* **294**, 1708–1712 (2001).
61. D. Herrmann, J. R. W. Conway, C. Vennin, A. Magenau, W. E. Hughes, J. P. Morton, P. Timpson, Three-dimensional cancer models mimic cell–matrix interactions in the tumour microenvironment. *Carcinogenesis* **35**, 1671–1679 (2014).
62. J. M. Barnes, J. T. Nauseef, M. D. Henry, Resistance to fluid shear stress is a conserved biophysical property of malignant cells. *PLOS ONE* **7**, e50973 (2012).
63. S. Frentzas, E. Simoneau, V. L. Bridgeman, P. B. Vermeulen, S. Foo, E. Kostaras, M. R. Nathan, A. Wotherspoon, Z.-h. Gao, Y. Shi, G. Van den Eynden, F. Daley, C. Peckitt, X. Tan, A. Salman, A. Lazaris, P. Gazinska, T. J. Berg, Z. Eltahir, L. Ritsma, J. van Rheenen, A. Khashper, G. Brown, H. Nyström, M. Sund, S. Van Laere, E. Loyer, L. Dirix, D. Cunningham, P. Metrakos, A. R. Reynolds, Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. *Nat. Med.* **22**, 1294–1302 (2016).
64. D. Wirtz, K. Konstantopoulos, P. C. Seanson, The physics of cancer: The role of physical interactions and mechanical forces in metastasis. *Nat. Rev. Cancer* **11**, 512–522 (2011).
65. A. Boudaoud, A. Burian, D. Borowska-Wykręta, M. Uyttewaal, R. Wrzaliak, D. Kwiatkowska, O. Hamant, FibrilTool, an ImageJ plugin to quantify fibrillar structures in raw microscopy images. *Nat. Protoc.* **9**, 457–463 (2014).
66. R. W. Scott, S. Hooper, D. Crighton, A. Li, I. König, J. Munro, E. Trivier, G. Wickman, P. Morin, D. R. Croft, J. Dawson, L. Machesky, K. I. Anderson, E. A. Sahai, M. F. Olson, LIM kinases are required for invasive path generation by tumor and tumor-associated stromal cells. *J. Cell Biol.* **191**, 169–185 (2010).
67. E. Hirata, M. R. Girotti, A. Viros, S. Hooper, B. Spencer-Dene, M. Matsuda, J. Larkin, R. Marais, E. Sahai, Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin $\beta 1$ /FAK signaling. *Cancer Cell* **27**, 574–588 (2015).
68. D. G. Duda, M. Ancukiewicz, S. J. Isakoff, I. E. Krop, R. K. Jain, Seeds and soil: Unraveling the role of local tumor stroma in distant metastasis. *J. Natl. Cancer Inst.* **106**, dju187 (2014).
69. A. Kumar, M. Ouyang, K. Van den Dries, E. J. McGhee, K. Tanaka, M. D. Anderson, A. Groisman, B. T. Goult, K. I. Anderson, M. A. Schwartz, Talin tension sensor reveals novel features of focal adhesion force transmission and mechanosensitivity. *J. Cell Biol.* **213**, 371–383 (2016).
70. Y. Wang, E. L. Botvinick, Y. Zhao, M. W. Berns, S. Usami, R. Y. Tsiens, S. Chien, Visualizing the mechanical activation of Src. *Nature* **434**, 1040–1045 (2005).
71. C.-W. Chang, Y.-S. Chen, C.-C. Chen, I.-O. Chan, C.-C. Chen, S.-J. Sheu, T.-w. Lin, S.-H. Chou, C.-J. Liu, T.-C. Lee, J.-F. Lo, Targeting cancer initiating cells by promoting cell differentiation and restoring chemosensitivity via dual inactivation of STAT3 and Src activity using an active component of *Antrrodia cinnamomea* mycelia. *Oncotarget* **7**, 73016–73031 (2016).
72. Q. Tan, H. Wang, Y. Hu, M. Hu, X. Li, Aodengqimuge, Y. Ma, C. Wei, L. Song, Src/STAT3-dependent heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to doxorubicin by promoting autophagy. *Cancer Sci.* **106**, 1023–1032 (2015).
73. M. Perez, A. Lucena-Cacace, L. M. Marin-Gomez, J. Padillo-Ruiz, M. J. Robles-Frias, C. Saez, R. Garcia-Carbonero, A. Carnero, Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src. *Oncotarget* **7**, 33111–33124 (2016).
74. S. Qin, B. Zhang, G. Xiao, X. Sun, G. Li, G. Huang, X. Gao, X. Li, H. Wang, C. Yang, H. Ren, Fibronectin protects lung cancer cells against docetaxel-induced apoptosis by promoting Src and caspase-8 phosphorylation. *Tumour Biol.* **37**, 13509–13520 (2016).
75. T. J. Yeatman, A renaissance for SRC. *Nat. Rev. Cancer* **4**, 470–480 (2004).
76. S. Zhang, D. Yu, Targeting Src family kinases in anti-cancer therapies: Turning promise into triumph. *Trends Pharmacol. Sci.* **33**, 122–128 (2012).
77. J. P. Morton, S. A. Karim, K. Graham, P. Timpson, N. Jamieson, D. Athineos, B. Doyle, C. McKay, M.-Y. Heung, K. A. Oien, M. C. Frame, T. R. J. Evans, O. J. Sansom, V. G. Brunton, Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. *Gastroenterology* **139**, 292–303 (2010).
78. T. Yokoyama, H. Goto, I. Izawa, H. Mizutani, M. Inagaki, Aurora-B and Rho-kinase/ROCK, the two cleavage furrow kinases, independently regulate the progression of cytokinesis: Possible existence of a novel cleavage furrow kinase phosphorylates ezrin/radixin/moesin (ERM). *Genes Cells* **10**, 127–137 (2005).
79. H. Kosako, T. Yoshida, F. Matsumura, T. Ishizaki, S. Narumiya, M. Inagaki, Rho-kinase/ROCK is involved in cytokinesis through the phosphorylation of myosin light chain and not ezrin/radixin/moesin proteins at the cleavage furrow. *Oncogene* **19**, 6059–6064 (2000).
80. P. Madaule, M. Eda, N. Watanabe, K. Fujisawa, T. Matsuoka, H. Bito, T. Ishizaki, S. Narumiya, Role of citron kinase as a target of the small GTPase Rho in cytokinesis. *Nature* **394**, 491–494 (1998).
81. A. Roy, L. Lordier, S. Mazzi, Y. Chang, V. Lapierre, J. Larghero, N. Debili, H. Raslova, W. Vainchenker, Activity of nonmuscle myosin II isoforms determines their localization at the cleavage furrow of megakaryocytes. *Blood* **128**, 3137–3145 (2016).
82. A. V. Biankin, N. Waddell, K. S. Kassahn, M.-C. Gingras, L. B. Muthuswamy, A. L. Johns, D. K. Miller, P. J. Wilson, A.-M. Patch, J. Wu, D. K. Chang, M. J. Cowley, B. B. Gardiner, S. Song, I. Harliwong, S. Idrisoglu, C. Nourse, E. Nourbakhsh, S. Manning, S. Wani, M. Gongora, M. Pajic, C. J. Scarlett, A. J. Gill, A. V. Pinho, I. Rooman, M. Anderson, O. Holmes, C. Leonard, D. Taylor, S. Wood, Q. Xu, K. Nones, J. L. Fink, A. Christ, T. Bruxner, N. Cloonan, G. Kolle, F. Newell, M. Pinese, R. S. Mead, J. L. Humphris, W. Kaplan, M. D. Jones, E. K. Colvin, A. M. Nagrial, E. S. Humphrey, A. Chou, V. T. Chin, L. A. Chantrill, A. Mawson, J. S. Samra, J. G. Kench, J. A. Lovell, R. C. Daly, N. D. Merrett, C. Toon, K. Epari, N. Q. Nguyen, A. Barbour, N. Zeps, Australian Pancreatic Cancer Genome Initiative, N. Kakkar, F. Zhao, Y. Q. Wu, M. Wang, D. M. Muzny, W. E. Fisher, F. C. Brunicardi, S. E. Hodges, J. G. Reid, J. Drummond, K. Chang, Y. Han, L. R. Lewis, H. Dinh, C. J. Buhay, T. Beck, L. Timms, M. Sam, K. Begley, A. Brown, D. Pai, A. Panchal, N. Buchner, R. De Borja, A. E. Denroche, C. K. Yung, S. Serra, N. Onetto, D. Mukhopadhyay, M.-S. Tsao, P. A. Shaw, G. M. Petersen, S. Gallinger, R. H. Hruban, A. Maitra, C. A. Iacobuzio-Donahue, R. D. Schulick, C. L. Wolfgang, R. A. Morgan, R. T. Lawlor, P. Capelli, V. Corbo, M. Scardon, G. Tortora, M. A. Tempero, K. M. Mann, N. A. Jenkins, P. A. Perez-Mancera, D. J. Adams, D. A. Largaespada, L. F. A. Wessels, A. G. Rust, L. D. Stein, D. A. Tuveson, N. G. Copeland, E. A. Musgrove, A. Scarpa, J. R. Eshleman, T. J. Hudson, S. R. L. Sutherland, D. A. Wheeler, J. V. Pearson, J. D. McPherson, R. A. Gibbs, S. M. Grimmond, Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. *Nature* **491**, 399–405 (2012).
83. S. R. Hingorani, W. P. Harris, A. E. Hendifar, A. J. Bullock, X. W. Wu, Y. Huang, P. Jiang, High response rate and PFS with PEGPH20 added to nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumors: Interim results of a randomized phase II study. *J. Clin. Oncol.* **33**, abstract 4006 (2015).
84. N. O. Carragher, A. Unciti-Broceta, D. A. Cameron, Advancing cancer drug discovery towards more agile development of targeted combination therapies. *Future Med. Chem.* **4**, 87–105 (2012).
85. P. Lu, V. M. Weaver, Z. Werb, The extracellular matrix: A dynamic niche in cancer progression. *J. Cell Biol.* **196**, 395–406 (2012).
86. F. Kai, H. Laklai, V. M. Weaver, Force matters: Biomechanical regulation of cell invasion and migration in disease. *Trends Cell Biol.* **26**, 486–497 (2016).
87. R. M. Vicari, B. Chaitman, D. Keefe, W. B. Smith, S. G. Chrysant, M. J. Tonkon, N. Bittar, R. J. Weiss, H. Morales-Ballejo, U. Thadani; Fasudil Study Group, Efficacy and safety of fasudil in patients with stable angina: A double-blind, placebo-controlled, phase 2 trial. *J. Am. Coll. Cardiol.* **46**, 1803–1811 (2005).
88. G. J. Liu, Z. J. Wang, Y. F. Wang, L. L. Xu, X. L. Wang, Y. Liu, G. J. Luo, G. H. He, Y. J. Zeng, Systematic assessment and meta-analysis of the efficacy and safety of fasudil in the treatment of cerebral vasospasm in patients with subarachnoid haemorrhage. *Eur. J. Clin. Pharmacol.* **68**, 131–139 (2012).
89. C. Braybrook, Fasudil as an adjunctive therapy for patients with stable angina. *Nat. Clin. Pract. Cardiovasc. Med.* **3**, 63–64 (2006).
90. N. N. Rahbari, D. Kedrin, J. Incio, H. Liu, W. W. Ho, H. T. Nia, C. M. Edrich, K. Jung, J. Daubriac, I. Chen, T. Heishi, J. D. Martin, Y. Huang, N. Maimon, C. Reissfelder, J. Weitz, Y. Boucher, J. W. Clark, A. J. Grodzinsky, D. G. Duda, R. K. Jain, D. Fukumura, Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases. *Sci. Transl. Med.* **8**, 360ra135 (2016).
91. S. M. Tolaney, Y. Boucher, D. G. Duda, J. D. Martin, G. Seano, M. Ancukiewicz, W. T. Barry, S. Goel, J. Lahdenranta, S. J. Isakoff, E. D. Yeh, S. R. Jain, M. Golshan, J. Brock, M. Snuderl, E. P. Winer, I. E. Krop, R. K. Jain, Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. *Proc. Natl. Acad. Sci. U.S.A.* **112**, 14325–14330 (2015).
92. P. Pantziarka, L. Cairns, Recycling existing drugs for cancer therapy: Delivering low cost cancer care. *Ecanermedicalscience* **8**, ed40 (2014).
93. J. T. Erler, K. L. Bennewith, T. R. Cox, G. Lang, D. Bird, A. Koong, Q.-T. Le, A. J. Giaccia, Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. *Cancer Cell* **15**, 35–44 (2009).
94. B. Psaila, D. Lyden, The metastatic niche: Adapting the foreign soil. *Nat. Rev. Cancer* **9**, 285–293 (2009).
95. N. Rath, J. P. Morton, L. Julian, L. Helbig, S. Kadir, E. J. McGhee, K. I. Anderson, G. Kalna, M. Mullin, A. V. Pinho, I. Rooman, M. S. Samuel, M. F. Olson, ROCK signaling promotes collagen remodeling to facilitate invasive pancreatic ductal adenocarcinoma tumor cell growth. *EMBO Mol. Med.* **9**, 198–218 (2017).
96. A. Patsialou, J. J. Bravo-Cordero, Y. Wang, D. Entenberg, H. Liu, M. Clarke, J. S. Condeelis, Intravital multiphoton imaging reveals multicellular streaming as a crucial component of in vivo cell migration in human breast tumors. *Intravital* **2**, e25294 (2013).

97. B. Wojciak-Stothard, A. J. Ridley, Shear stress–induced endothelial cell polarization is mediated by Rho and Rac but not Cdc42 or PI 3-kinases. *J. Cell Biol.* **161**, 429–439 (2003).
98. R. Vishnubhotla, S. Bharadwaj, S. Sun, V. Metlushko, S. C. Glover, Treatment with Y-27632, a ROCK inhibitor, increases the proinvasive nature of SW620 cells on 3D collagen type 1 matrix. *Int. J. Cell Biol.* **2012**, 259142 (2012).
99. R. Torka, F. Thuma, V. Herzog, G. Kirfel, ROCK signaling mediates the adoption of different modes of migration and invasion in human mammary epithelial tumor cells. *Exp. Cell Res.* **312**, 3857–3871 (2006).
100. L. Bhandary, R. A. Whipple, M. I. Vitolo, M. S. Charpentier, A. E. Boggs, K. R. Chakrabarti, K. N. Thompson, S. S. Martin, ROCK inhibition promotes microtubules that enhance reattachment of breast cancer cells. *Oncotarget* **6**, 6251–6266 (2015).
101. K. P. Garnock-Jones, Ripasudil: First global approval. *Drugs* **74**, 2211–2215 (2014).
102. N. Kaneko, T. Mashiko, T. Ohnishi, M. Ohta, K. Namba, E. Watanabe, K. Kawai, Manufacture of patient-specific vascular replicas for endovascular simulation using fast, low-cost method. *Sci. Rep.* **6**, 39168 (2016).
103. S. Boland, A. Bourin, J. Alen, J. Geraets, P. Schroeders, K. Castermans, N. Kindt, N. Boumans, L. Panitti, S. Fransen, J. Vanormelingen, J. M. Stassen, D. Leysen, O. Defert, Design, synthesis, and biological evaluation of novel, highly active soft ROCK inhibitors. *J. Med. Chem.* **58**, 4309–4324 (2015).
104. A. Sadok, A. McCarthy, J. Caldwell, I. Collins, M. D. Garrett, M. Yeo, S. Hooper, E. Sahai, S. Kuemper, F. K. Mardakheh, C. J. Marshall, Rho kinase inhibitors block melanoma cell migration and inhibit metastasis. *Cancer Res.* **75**, 2272–2284 (2015).
105. F. Bertolini, V. P. Sukhatme, G. Bouche, Drug repurposing in oncology—Patient and health systems opportunities. *Nat. Rev. Clin. Oncol.* **12**, 732–742 (2015).
106. P. S. Steeg, Targeting metastasis. *Nat. Rev. Cancer* **16**, 201–218 (2016).
107. M. Pajic, D. Herrmann, C. Vennin, J. R. W. Conway, V. T. Chin, A.-K. E. Johansson, H. C. E. Welch, P. Timpson, The dynamics of Rho GTPase signaling and implications for targeting cancer and the tumor microenvironment. *Small GTPases* **6**, 123–133 (2015).

Acknowledgments: We thank H. Bennett and K. Murphy for critical reading of the manuscript.

Funding: This study was supported by the National Health and Medical Research Council (NHMRC), Cancer Council NSW, Cancer Australia, Tour de Cure grants, Cancer Institute NSW, the Australian Research Council Future Fellowships, The Avner Pancreatic Cancer Foundation, Lens Ainsworth and Philip Hemstritch Pancreatic Cancer Fellowships, Sydney Catalyt scholarships, Royal Australasian College of Physicians Research Foundation scholarships, Pancare Australia stipend, NHMRC scholarships, a Cancer Research UK core grant, and a Patricia Helen Guest Fellowship. T.R.J.E. received funding for clinical trials (payable to the Institution) from Celgene, Bristol-Myers Squibb, AstraZeneca, Bayer, Roche, and Basilea.

Author contributions: Investigation, validation, and formal analysis: C.V., V.T.C., S.C.W., M.C.L., D.H., P.M., S.N.W., G.d.M.-N., A.A.S., S.T.G., A.M., A.H.A., R.A.C., J.R.W.C., M.N., M. Pinese, A. Boulghourjian, A.Z., A.M.N., N.C., R.J., W.W., A.C., A.S., A.D., D.F., C.H., M.G.-L., D.G.-O., N.L.E.H., R.W., A.L.J., J.S.S., L.C., T.R.C., A.J.G., A. Burgess, and A.P.G.I. Conceptualization and funding acquisition: C.V., S.C.W., D.H., T.P., A. Burgess, O.J.S., A.V.B., M.K.-C., Y.W., M.S.S., T.R.C., J.P.M., C.J.O., M. Pajic, and P.T. Methodology: C.V., S.C.W., M.C.L., D.H., A.M., S.N.W., G.d.M.-N., A. Boulghourjian, A.Z., E.J.G., S.T.G., R.P.H., Y.W., M.S.S., T.R.J.E., K.I.A., A. Burgess, T.R.C., J.P.M., M. Pajic, and P.T. Writing and visualization: C.V., P.T., and M. Pajic.

Competing interests: The authors declare that they have no competing interests.

Members of APGI Consortium: Amber L. Johns¹, Anthony J. Gill^{1,2}, David K. Chang^{1,3}, Christopher J. Scarlett¹, Skye H. McKay¹, Lorraine A. Chantrill^{1,4}, Venessa T. Chin¹, Angela Chou¹, Mark J. Cowley¹, Jeremy L. Humphris¹, Marina Pajic¹, Angela Steinmann¹, Mehreen Arshi¹, Ali Drury¹, Danielle Froio¹, Ashleigh Morgan¹, Paul Timpson¹, David Herrmann¹, Claire Vennin¹, Sean C. Warren¹, Mark Pinese¹, Jianmin Wu¹, Andrea V. Pinho¹, Nicola Waddell⁵, Ann-Marie Patch⁵, John V. Pearson⁵, Sarah Song⁵, Suzanne Manning⁵, Shivangi Wani⁵, Milena Gongora⁵, Matthew Anderson⁵, Oliver Holmes⁵, Conrad Leonard⁵, Darrin Taylor⁵, Scott Wood⁵, Christina Xu⁵, Katia Nones⁵, J. Lynn Fink⁵, Felicity Newell⁵, Michael Quinn⁵, Stephen Kazakoff⁵, Nick Waddell⁵, Keerthana Krisnan⁵, David Wood⁵, Sean M. Grimmond², Oliver Hofmann², Peter J. Wilson⁶, Angelika Christ⁶, Tim Bruxner⁶, Jaswinder S. Samra⁷, Anthony J. Gill⁷, Nick Pavlakis⁷, Hilda A. High⁷, Ray Asghari⁸, Neil D. Merrett⁸, Darren Pavey⁸, Amitabha Das⁸, Peter H. Cosman⁹, Kasim Ismail⁹,

Chelsie O’Connor⁹, Alina Stoita⁴, David Williams⁴, Allan Spigellman⁴, Vincent W. Lam¹⁰, Duncan McLeod¹⁰, Henry C. Pleass¹⁰, Adnan M. Nagrial^{1,10}, Judy Kirk¹⁰, Virginia James¹⁰, James G. Kench¹¹, Peter Grimison¹¹, Caroline L. Cooper¹¹, Charbel Sandroussi¹¹, Michael Crawford¹¹, Annabel Goodwin^{9,11}, R. Scott Mead^{9,11,12}, Katherine Tucker¹², Lesley Andrews¹², Michael Textler¹³, Cindy Forest¹³, Andrew Laycock¹³, Krishna P. Epari¹³, Mo Ballal¹³, David R. Fletcher¹³, Sanjay Mukhedkar¹³, Nigel A. Spry¹⁴, Bastiaan DeBoer¹⁴, Ming Chai¹⁴, Nikolajs Zeps¹⁵, Maria Beilin¹⁵, Kynan Feeney¹⁵, Nan Q. Nguyen¹⁶, Andrew R. Ruszkiewicz¹⁶, Chris Worthley¹⁶, John Chen¹⁷, Mark E. Brooke-Smith¹⁷, Virginia Papangelis¹⁷, Andrew D. Clouston¹⁸, Patrick Martin¹⁸, Andrew P. Barbour¹⁹, Thomas J. O’Rourke¹⁹, Jonathan W. Fawcett¹⁹, Kellee Slater¹⁹, Michael Hatzifotis¹⁹, Peter Hodgkinson¹⁹, Christopher Christophi²⁰, Mehrdad Nikfarjam²⁰, James R. Eshleman²¹, Ralph H. Hruban²¹, Richard D. Schulick²¹, Christopher L. Wolfgang²¹, Richard A. Morgan²¹, Mary Hodgjin²¹, Aldo Scarpa³, Rita T. Lawlor³, Stefania Beghelli³, Vincenzo Corbo³, Maria Scardoni³, Claudio Bassi³, Andrew V. Biankin^{1,22}, David K. Chang^{1,22}, Peter Bailey²², Sancha Martin²², Elizabeth A. Musgrove²², Marc D. Jones²², Craig Nourse²², Nigel B. Jamieson²²

¹The Kinghorn Cancer Centre, Garvan Institute of Medical Research, 370 Victoria Street, Darlinghurst, Sydney, New South Wales 2010, Australia. ²Centre for Cancer Research, Victorian Comprehensive Cancer Centre, University of Melbourne, 305 Grattan Street, Melbourne, Victoria 3000, Australia. ³ARC-NET Center for Applied Research on Cancer, University of Verona, Via dell’Artiglierie, 19 37129 Verona, Province of Verona, Italy. ⁴St. Vincent’s Hospital, 390 Victoria Street, Darlinghurst, New South Wales, 2010 Australia. ⁵Queensland Institute of Medical Research Berghofer Medical Research Institute, 300 Herston Road, Herston, Queensland 4006, Australia. ⁶Institute for Molecular Bioscience, University of Queensland, St Lucia, Queensland 4072, Australia. ⁷Royal North Shore Hospital, Westbourne Street, St Leonards, New South Wales 2065, Australia. ⁸Bankstown Hospital, Eldridge Road, Bankstown, New South Wales 2200, Australia. ⁹Liverpool Hospital, Elizabeth Street, Liverpool, New South Wales 2170, Australia. ¹⁰Westmead Hospital, Hawkesbury and Darcy Roads, Westmead, New South Wales 2145, Australia. ¹¹Royal Prince Alfred Hospital, Missenden Road, Camperdown, New South Wales 2050, Australia. ¹²Prince of Wales Hospital, Barker Street, Randwick, New South Wales 2031, Australia. ¹³Fremantle Hospital, Alma Street, Fremantle, Western Australia 6959, Australia. ¹⁴Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, Western Australia 6009, Australia. ¹⁵St. John of God Healthcare, 12 Salvado Road, Subiaco, Western Australia 6008, Australia. ¹⁶Royal Adelaide Hospital, North Terrace, Adelaide, South Australia 5000, Australia. ¹⁷Flinders Medical Centre, Flinders Drive, Bedford Park, South Australia 5042, Australia. ¹⁸Envoi Pathology, 1/49 Butterfield Street, Herston, Queensland 4006, Australia. ¹⁹Princess Alexandra Hospital, Cornwall Street, Ipswich Road, Woolloongabba, Brisbane, Queensland 4102, Australia. ²⁰Austin Hospital, 145 Studley Road, Heidelberg, Victoria 3084, Australia. ²¹Johns Hopkins Medical Institute, 600 North Wolfe Street, Baltimore, MD 21287, USA. ²²Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Bearsden, Glasgow, Scotland G61 1BD, UK.

Submitted 6 September 2016

Resubmitted 21 December 2016

Accepted 4 March 2017

Published 5 April 2017

10.1126/scitranslmed.aai8504

Citation: C. Vennin, V. T. Chin, S. C. Warren, M. C. Lucas, D. Herrmann, A. Magenau, P. Melenc, S. N. Walters, G. del Monte-Nieto, J. R. W. Conway, M. Nobis, A. H. Allam, R. A. McCloy, N. Currey, M. Pinese, A. Boulghourjian, A. Zaratian, A. A. S. Adam, C. Heu, A. M. Nagrial, A. Chou, A. Steinmann, A. Drury, D. Froio, M. Giry-Laterriere, N. L. E. Harris, T. Phan, R. Jain, W. Wenginger, E. J. McGhee, R. Whan, A. L. Johns, J. S. Samra, L. Chantrill, A. J. Gill, M. Kohonen-Corish, R. P. Harvey, A. V. Biankin, Australian Pancreatic Cancer Genome Initiative (APGI), T. R. J. Evans, K. I. Anderson, S. T. Grey, C. J. Ormandy, D. Gallego-Ortega, Y. Wang, M. S. Samuel, O. J. Sansom, A. Burgess, T. R. Cox, J. P. Morton, M. Pajic, P. Timpson, Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. *Sci. Transl. Med.* **9**, eai8504 (2017).

Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis

Claire Vennin, Venessa T. Chin, Sean C. Warren, Morghan C. Lucas, David Herrmann, Astrid Magenau, Pauline Melenc, Stacey N. Walters, Gonzalo del Monte-Nieto, James R. W. Conway, Max Nobis, Amr H. Allam, Rachael A. McCloy, Nicola Currey, Mark Pinese, Alice Boulghourjian, Anais Zaratzian, Arne A. S. Adam, Celine Heu, Adnan M. Nagrial, Angela Chou, Angela Steinmann, Alison Drury, Danielle Froio, Marc Giry-Laterriere, Nathaniel L. E. Harris, Tri Phan, Rohit Jain, Wolfgang Weninger, Ewan J. McGhee, Renee Whan, Amber L. Johns, Jaswinder S. Samra, Lorraine Chantrill, Anthony J. Gill, Maija Kohonen-Corish, Richard P. Harvey, Andrew V. Biankin, Australian Pancreatic Cancer Genome Initiative (APGI), T. R. Jeffrey Evans, Kurt I. Anderson, Shane T. Grey, Christopher J. Ormandy, David Gallego-Ortega, Yingxiao Wang, Michael S. Samuel, Owen J. Sansom, Andrew Burgess, Thomas R. Cox, Jennifer P. Morton, Marina Pajic and Paul Timpson (April 5, 2017)
Science Translational Medicine 9 (384), . [doi: 10.1126/scitranslmed.aai8504]

Editor's Summary

ROCK-ing pancreatic cancer to the core

Pancreatic cancer, one of the most deadly and difficult-to-treat tumor types in patients, usually has a dense stroma that can be difficult for drugs to penetrate. Stromal characteristics can also affect multiple other aspects of tumor biology, including metastatic spread, vascular supply, and immune response. Vennin *et al.* used Fasudil, a drug that inhibits a protein called ROCK and is already used for some conditions in people, to demonstrate the feasibility including short-term tumor stroma remodeling as part of cancer treatment. In genetically engineered and patient-derived mouse models of pancreatic cancer, priming with Fasudil disrupted the tumors' extracellular matrix and improved the effectiveness of subsequent treatment with standard-of-care chemotherapy for this disease.

The following resources related to this article are available online at <http://stm.sciencemag.org>.
This information is current as of April 5, 2017.

Article Tools Visit the online version of this article to access the personalization and article tools:
<http://stm.sciencemag.org/content/9/384/eaai8504>

Supplemental Materials "*Supplementary Materials*"
<http://stm.sciencemag.org/content/suppl/2017/04/03/9.384.eaai8504.DC1>

Science Translational Medicine (print ISSN 1946-6234; online ISSN 1946-6242) is published weekly, except the last week in December, by the American Association for the Advancement of Science, 1200 New York Avenue, NW, Washington, DC 20005. Copyright 2017 by the American Association for the Advancement of Science; all rights reserved. The title *Science Translational Medicine* is a registered trademark of AAAS.

Related Content

The editors suggest related resources on *Science's* sites:

<http://stm.sciencemag.org/content/scitransmed/3/108/108ra113.full>

<http://stm.sciencemag.org/content/scitransmed/4/156/156ps21.full>

<http://stm.sciencemag.org/content/scitransmed/4/156/156ra139.full>

<http://stm.sciencemag.org/content/scitransmed/8/360/360ra135.full>

Permissions

Obtain information about reproducing this article:

<http://www.sciencemag.org/about/permissions.dtl>

Science Translational Medicine (print ISSN 1946-6234; online ISSN 1946-6242) is published weekly, except the last week in December, by the American Association for the Advancement of Science, 1200 New York Avenue, NW, Washington, DC 20005. Copyright 2017 by the American Association for the Advancement of Science; all rights reserved. The title *Science Translational Medicine* is a registered trademark of AAAS.